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Novel Chemical Tools and Methods for Quantitative Mass 
Spectrometry-Based Proteomics 
Adam Jay McShane, Ph.D. 
University of Connecticut, 2015 
Abstract 
Mass spectrometry-based proteomics utilizes a mass spectrometer to study the identity, 
quantity, localization, modification, interaction, and function of proteins.  This technology was 
applied to quantify cystic fibrosis transmembrane conductance regulator (CFTR) protein, whose 
mutation is responsible for the lethal disease cystic fibrosis.  Mutated CFTR is degraded before it 
reaches the plasma membrane (PM), where it performs its vital function as a chloride ion channel.  
The first step of drug modulation is to increase the expression of CFTR in the PM; thus, an accurate 
measurement of CFTR in the PM is desired.  A tandem enrichment strategy of cell-surface 
biotinylation and gel electrophoretic enrichment, with pulse chase of stable isotopes, was applied 
to measure the lifetime of CFTR, in the apical PM of BHK-wtCFTR cells.  The half-life was 
determined to be 29.0±2.5h.  Quantitation and turnover measurements of CFTR in the apical PM 
can significantly facilitate the understanding of the cystic fibrosis disease mechanism and thus the 
development of new disease-modifying drugs. 
CFTR and all proteomic quantitation suffers from low sample numbers and replicates due 
to lengthy analysis time.  However, small changes in protein concentration demand increased 
samples and replicates to ensure statistical and analytical relevance.  Towards increasing the 
throughput of CFTR quantitation, an ultrathroughput multiple reaction monitoring (uMRM) 
method was designed. CFTR digest samples, containing one common internal standard, were 
derivatized with unique mass tags.  Derivatized, cysteinyl CFTR peptides were then enriched with 
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an avidin/biotin pull-down strategy before MRM measurements. A 5-plex experiment was 
designed, and will be compared to traditional MRM measurements of the 5 samples analyzed 
individually. To evaluate a possible new mass tagging strategy for uMRM, the collisional 
fragmentation of peptides whose amine groups were derivatized with five linear ω-dimethylamino 
acids, from 2-(dimethylamino)-acetic acid to 6-(dimethylamino)-hexanoic acid, were investigated. 
Tandem mass spectra of the derivatized peptides revealed different preferential breakdown 
pathways. Together with energy resolved mass spectrometry, it was found that shutting down the 
active participation of the terminal dimethylamino group in fragmentation of derivatized peptides 
is possible. However, it took a separation of five methylene groups between the terminal 
dimethylamino group and the amide formed upon peptide derivatization. 
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1.1 Introduction 
Proteomics is the study of the protein complement from a particular biological system like 
a tissue, cell type, or organism. The study includes the protein identity, quantity, localization, 
modification, interaction, and function. The focus of this chapter is on current quantitative 
proteomic approaches including immuno-based detection and mass spectrometry-based analysis. 
With the impact of quantitative proteomics in biological sciences, the goal of the chapter is to take 
the novice in proteomic quantitation through the fundamentals of the field to current, cutting edge 
methods, as well as to provide a collection of current literature on the topic for proteomics 
practitioners. The bulk of the material focuses on mass spectrometry-based detection methods with 
sections on derivatization-free and derivatization-based quantitation, activity probes, mass 
spectrometers, sample enrichment techniques, software, and throughput considerations. 
1.2 Immuno-based detection methods 
1.2.1 Gel-based approaches 
In the 1970’s, one dimensional gel electrophoresis (1-DE) was introduced as a separation 
method for the determination of protein molecular weight and for assessing protein purity [1]. The 
most popular electrophoretic techniques for protein separation are isoelectric focusing (IEF) using 
immobilized pH gradients (IPGs), and sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE). Proteins are separated based on their isoelectric point (pI) in IEF, whereas SDS-
PAGE separates based on size [2]. In 1975, 2-DE was developed to separate proteins using IEF as 
the first dimension and SDS-PAGE as the second dimension. Modern 2-DE methods still have 
similar designs [2,3]. 
Different methods have been used to visualize proteins after SDS-PAGE separation. Silver 
staining due to the excellent detectability is among the most routinely used technique; however, it 
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is not quantitative because it has varying interactions with different proteins and a limited dynamic 
range. Staining gels using Colloidal Coomassie Blue leads to a better linear dynamic range but 
relatively compromised limit of detection. Fluorescent labeling has gained popularity due to its 
sensitivity and wide linear dynamic range [4]. 
1.2.1.1 Fluorescent two-dimensional difference gel electrophoresis (2-D DIGE)   
Despite of the high resolving power, 2-DE has inherent limitations. It suffers from poor 
sensitivity, low solubilization of membrane proteins, low throughput, and limited gel to gel 
reproducibility [4-6]. Other reported drawbacks are labor-intensive image analysis and poor 
representation of extremely acidic or basic proteins as well as small proteins [7,8]. The inherent 
variability of 2-DE has been addressed by the emergence of fluorescent 2-D DIGE [4-6]. In 2-D 
DIGE, amine groups of proteins are covalently labeled with 2 spectrally resolvable n-
hydroxysuccinimide (NHS) fluorescent dyes, cynine dyes (Cy3 and Cy5), prior to protein 
separation. To ensure that the same proteins in both samples for comparison have the same relative 
2-DE mobility, the dyes have the same mass and charge [4]. Fluorescent labeling also renders 2-
D DIGE much more quantitative than colorimetric methods. It has a linear dynamic range of 4 to 
5 orders of magnitude, compared to 1 to 3 orders with staining methods [9]. 
1.2.1.2 Western blots (immunoblotting) 
Western blots are a fundamental tool for the measurement of proteins in biomedical labs.  
The western blot utilizes antibodies that are specific to the protein of interest for detection.  From 
1979 to 1981, 3 papers were published with the first use of this method [10-12]. Generally, gel 
electrophoresis is performed first to separate proteins.  The proteins are then transferred to a 
membrane [polyvinylidene fluoride (PVDF) and nitrocellulose membranes are commonly used].  
After the transfer, primary and secondary antibodies are added consecutively. Finally, the signal 
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is produced by adding detection reagents (e.g. chromogenic and colorimetric) to the secondary 
antibodies. A general procedure is displayed in Figure 1.1. Recent technological updates to 
western blotting include quantum dot (QD) conjugation [13-15], microfluidic engineering [16-20], 
and imagers (e.g. ChemiDoc™ and G:Box). 
 
Figure 1.1: Generic western blotting steps. 
1.2.2 Non-gel-based approaches 
1.2.2.1 Enzyme-linked immunosorbent assays (ELISA) and aptamer-based assays 
ELISA uses antibodies and surface binding to accomplish detection. This can be done by 
indirect antigen binding to the surface or direct antigen binding to antibodies on the surface [21]. 
Like western blotting the antigen is recognized with an antibody that has an enzyme covalently 
linked (e.g., horseradish peroxidase). The predecessor to ELISA was described in 1960 [22]. 
Recent advancements push the detection limit of ELISA to subfemtomolar concentrations [23,24]. 
The popularity of aptamer-based assays has risen over the last several years in proteomics [25]. 
Typical aptamers are singly-stranded nucleic acids that can recognize target molecules. The 
general basis is similar to immuno-based methods. These aptamers are found by screening large 
libraries of nucleic acid sequences. This technology has been applied to several proteome-level 
detections [26-29]. 
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1.2.2.2 Surface plasmon resonance (SPR) spectroscopy 
SPR spectroscopy is a phenomenon that occurs on an electron rich metal surface (active 
surface) upon the impact of an incident light with a certain frequency. Techniques based on SPR 
detect any change of the refractive index on the active surface due to the adsorption of a target 
analyte [30]. For protein detection, antibodies are extensively used to modify the SPR active 
surface. As detailed in Figure 1.2, the 4 major mechanisms of the antibody-based SPR reported 
are direct [31], competitive [32], sandwich [33], and inhibition assays [34]. Using antibody arrays 
leads to an extension of the technique that is referred to as surface plasmon resonance imaging 
(SPRI). This technique is a high-throughput and multiplexible version of SPR. Biological SPR is 
categorized as a label-free quantitation method. Thus, there is no need for elaborate sample 
preparation, which allows for fast, real-time, and reusable sensing [35]. This technique suffers 
from 2 common antibody-based detection problems: the high cost of immunograde antibodies and 
non-specific binding of proteins. A vast variety of modifications and alterations have been made 
to the active surface of SPR to enhance the selectivity and sensitivity of the SPR sensor. The use 
of nanoparticles together with an immunodetection sandwich compartment is one popular 
approach [36-38]. This approach has been applied for amplified detection of total prostate-specific 
antigen (tPSA) [39]. Aptamers are an alternative to protein-based antibodies [40]. Nanostructures 
(i.e. nanowires, nanoholes and nano-layers) on the active surface have been used to increase 
antigen binding [41,42]. Using these versatile signal enhancement techniques, achieving an 
attomolar limit of detection for proteins is possible [43]. 
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Figure 1.2: Detection mechanisms in SPR-based sensors. A) Direct assay: direct detection of 
analyte B) Competitive assay: analyte competes with an internal standard C) Sandwich assay: 
analyte is trapped between 2 antibodies D) Inhibition assay: analyte is pretreated with an antibody.i 
 
1.2.2.3 Lab-on-a-chip 
The incorporation of microfluidics into small devices that are capable of analysis or 
experimentation is commonly referred to as “lab-on-a-chip” [44]. These small devices have been 
used in a variety of ways. Liquid chromatography (LC) on-chip approaches are well represented 
in the literature [45,46]. These chips have also been used to study the membrane proteome [47] 
and protein-protein interaction via fluorescence resonance energy transfer (FRET) [48]. Further 
examples of technology miniaturization can be found in journals dedicated to the on-chip 
methodology (i.e. Lab-on-a-Chip). 
1.3 MS-based detection methods 
1.3.1 Introduction 
Among various technologies used in quantitative proteomics, MS steps out as the major 
player in the field. Fast, reproducible, and capable of analyzing highly complex samples are some 
advantages of MS-based quantitation methods [49]. Two major approaches in MS-based 
proteomic quantitation are derivatization-based and derivatization-free. Selecting a particular 
approach for proteomic analysis depends on many factors [50]. In a derivatization-free approach, 
                                                          
i Figure by Vahid Farrokhi. McShane, A. J.; Farrokhi, V.; Nemati, R.; Li, S.; Yao, X. An Overview of Quantitative 
Proteomic Approaches. Comprehensive Analytical Chemistry, Oxford, UK; Elsevier, 2014; p. 111-135. 
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there is no concern of the completion and efficiency of chemical reactions or subsequent sample 
cleanup. Thus this approach delivers a faster and more straightforward solution for a large-scale 
primary study. Derivatization-based approaches, however, deliver more flexibility and improved 
sample throughput. Figure 1.3 categorizes different derivatization-free and derivatization-based 
quantitation methods. The 2 schools of proteomic research use either direct MS analysis of proteins 
(top-down proteomics) or analysis of peptides resulted from proteolytic digestion of proteome 
samples (bottom-up proteomics or shotgun proteomics) [51]. However, the majority of quantitative 
analysis in proteomics use the bottom-up principle, in which the peptide quantity is representative 
of protein amount [52]. This chapter will only focus on bottom-up techniques for proteomic 
quantitation. 
 
Figure 1.3: Categorization of MS-based proteomics quantitation approaches. 
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1.3.2 Mass spectrometers 
Mass spectrometers are composed of 3 main components: the ionization source, the mass 
analyzer, and the detector. With the development of different mass analyzers, the choice of mass 
spectrometer for a specific analysis becomes critical [53]; e.g., if the analysis is to quantitatively 
profile all proteins in a sample or quantify a pre-selected set of protein targets. One or a 
combination of mass analyzers, such as time of flight (TOF), quadrupole (Q), ion trap (IT), ion 
cyclotron resonance (ICR), and OrbitrapTM, can be implemented in MS or tandem MS (MS/MS). 
For non-targeted quantitative proteomics, in which the protein profiling and relative quantitation 
is performed simultaneously, mass spectrometers with high accuracy and resolution such as Q-
TOF, TOF-TOF, or OrbitrapTM are preferred. Mass resolving power and accuracy, which are 
continuously being improved in new commercial instruments, are the important factors necessary 
for software-assisted protein identification with high statistical confidence [54]. TOF analyzers are 
the most traditional analyzer for delivering high mass accuracy and resolution, together with great 
speed of analysis [55]. An OrbitrapTM analyzer works based on complex electrostatic fields applied 
between inner and outer electrodes to trap ions. Ions are resolved around the inner electrode 
depending on the applied electrostatic frequency and the mass-to-charge ratio (m/z) of ions [56]. 
Hybrid versions of the Orbitrap [e.g. linear ion trap-Orbitrap (LTQ-orbitrap™)] have been utilized 
for protein identification and quantitation [57]. Based on the fundaments of the ion trap, ion 
movements are controlled by alternating current (AC) and direct current (DC) electric fields that 
are dynamically trapping, stabilizing, or filtering out the ions depending on the mode of the 
analysis [58]. Q-TOF instruments are another type of tandem mass spectrometers for global protein 
profiling and quantitation [59]. The quadrupole is usually used for its ion filtering capability as the 
first mass analyzer in hybrid instruments. Quadrupole analyzers use AC and DC electric field to 
 9 
 
stabilize or destabilize ions with different m/z ratios, thus often referred to as mass filters; these 
analyzers are typically operated at modes with low mass resolution and accuracy [60]. 
Mass filtering capability of quadrupole analyzers makes triple quadrupole (QqQ) mass 
spectrometers suitable for targeted proteomic quantitation. These instruments are used in the mode 
of multiple reaction monitoring (MRM) analysis [61]. Alternative approaches for targeted 
proteomic quantitation have been reported newly developed hybrid instruments. A quadrupole-
orbitrap platform (Q Exactive™) is able to deliver pseudomultiple reaction monitoring (pMRM) 
analysis. It can also perform the method of parallel reaction monitoring in which a full scan of 
MS/MS data is achievable from all the precursors and fragments in high resolution and the needed 
information is extracted after data acquisition [62]. A recent exploration of the Q-TOF instrument 
performs parallel selection and fragmentation of a range of precursor ions [63-65]. 
1.3.3 Derivatization-free techniques 
1.3.3.1 Label-free quantitation 
Label-free quantitation is the simplest, fastest, and cleanest amongst all the MS-based 
quantitation methods. It has been frequently used in shotgun proteomics in which the protein 
profiling/quantitation is performed on a large scale and in a non-targeted fashion [66]. The sample 
goes through the least manipulation before MS analysis. The label-free quantitation can be done 
based on 1) ion intensity or peak area measurement in the chromatogram for an intact peptide and 
2) spectral counting of the fragment ions from all the peptides (originated from a single protein) 
in a MS/MS-based analysis. Spectral counting is implemented in a data dependent acquisition 
(DDA) mode. In a DDA tandem mode, selected precursor ions are subjected to fragmentation 
when their abundances are above a user-set, predefined level. DDA mode-based spectral counting 
shows good correlation with the protein abundance [67]. However, this method is not 
 10 
 
recommended for low abundance proteins due to poor accuracy. Software to assist in label-free 
quantitation includes an ion intensity chromatogram measurement called MS1 filtering. This 
increases peak selection accuracy by incorporating the peptide retention time [68]. Another 
software program takes advantage of simultaneous spectral counting and a total ion chromatogram 
to enhance the analysis quality [69]. 
1.3.3.2 Label-assisted quantitation 
With the label-free methods in the repertoire of quantitative proteomics practitioners, there 
is still a need for label-assisted methods to perform quantitation with improved accuracy and 
precision. Label-assisted methods incorporate stable isotope labels into internal standards (IS) for 
quantitation; this MS-based quantitation method is termed stable isotope dilution (SID). The 
incorporation of stable isotope labels can be achieved either without or with chemical 
derivatization of proteome samples. Use of metabolic labeling, absolute quantitation (AQUA) 
peptides, and 18O labeling are three common derivatization-free methods. 
1.3.3.2.1 Metabolic labeling 
Metabolic labeling is capable of labeling the whole proteome in cells or an entire organism. 
Metabolic labeling of cells is accomplished by the addition of isotopically labeled amino acids into 
the cell culture media which lacks the same, but non-isotopically labeled amino acids. Each stable 
isotope label is commonly 1 or 2 Da higher in mass, such as 15N and 13C. Stable isotope labeling 
with amino acids in cell culture (SILAC) is the most popular method of metabolic labeling [70]. 
The comprehensiveness and relative simplicity of SILAC makes it commonly used for the relative 
quantitation of proteome samples [71-73]. Labeling proteins is advantageous because it allows for 
more accurate quantitation due to the early addition of the IS in sample preparation. This mitigates 
the sample loss variations from the downstream manipulation, including protein fractionation and 
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separation, digestion, and peptide separation. A drawback is that it is not applicable to tissue 
samples or biological fluids, such as plasma and urine. However, an altered approach that uses 
stable isotope labeled proteome (SILAP) as the IS applies the same metabolic labeling concept to 
the secretome of a cell line(s) [72]. It was used to make a secretome IS from CAPAN-2 human 
pancreatic cancer derived cells for relative quantitation of sera proteins from early-stage pancreatic 
cancer patients. SILAP has also been utilized to investigate different biomarkers for prostate 
cancer [74]. Stable isotope labeling of mammals (SILAM) is an adapted approach to make the 
metabolic labeling compatible with tissue analysis [75]. This was accomplished in rats with 15N-
enriched spirulina diet. Providing an IS for tissue allows for quantitative pathway analysis [76,77]. 
 Another developed solution for the tissue proteome analysis is super-SILAC [71]. In this 
approach, labeled proteins are provided from multiple cell lines and used as a combined IS. The 
cell lines are pooled together to better represent a tissue proteome. Another SILAC derivative is 
the method of in vivo termini amino acid labeling (IVTAL) [78]. This method couples 2 different 
endoproteases (Arg-C and Lys-N) and 2 different cell culture media (heavy arginine and heavy 
lysine) to produce isobaric peptides that have varied MS fragment ions [78]. 
1.3.3.2.2 Absolute quantitation (AQUA) peptides 
Absolute quantitation allows for direct comparison of proteomic data obtained on different 
instruments and in different laboratories. The need to measure the absolute abundance of proteins 
is achievable using a targeted quantitation approach. A synthetic, isotopically labeled peptide is 
used as the IS. This peptide is the isotopic counterpart of a signature peptide, which represents a 
1:1 ratio with the corresponding protein. There are a number of cautions that need to be considered 
to choose an endogenous peptide as a signature of the target protein. The signature peptide 
quantitatively represents the target, therefore should be a stoichiometric equivalence of the protein 
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[i.e. lacking co/post-translational modifications (PTMs)]. Digestion efficiency, peptide 
uniqueness, and a number of other peptide selection criteria should be considered in choosing the 
signature peptide [79]. This type of quantitation is often performed via tandem MS specifically on 
a MRM platform [80]. Unlike metabolic labeling, AQUA is applicable to quantitation of 
proteomes of almost every biological source such as tissues, plasma, or cells. Absolute quantitation 
using synthetic heavy peptides is among the most popular methods for quantitative analysis in 
system biology and therapeutics and biomarker development [81-84]. 
1.3.3.2.3 18O labeling 
Isotope labeling of proteome samples can be achieved via enzymatic 18O replacement of 
16O on carboxylic groups at C-termini of peptides from proteome digests [85,86]. The source of 
18O is H2
18O comprised buffer. Enzymatic 18O labeling globally incorporates two 18O atoms at the 
C-terminus carboxyl group of almost all of the peptides of a proteome digest. Use of enzymes in 
immobilized formats allows for efficient post-labeling removal and thus eliminating back-
exchange of 18O labels [87]. In-gel 18O labeling has been found to facilitate protein identification 
and quantification [88]. 18O labeling initially developed for relative quantitation has also been 
adapted for absolute quantitation of proteins [89,90]. Studies of protein PTMs is another 
application area. 18O labeling has been utilized for quantitation of phosphorylation [91] and 
deamidation [92,93]. Acid catalysis can also exchange peptidyl carboxylate oxygen atoms, but in 
a non-selective manner [94,95]. Due to drawbacks like residue and peptide sequence dependence 
of the labeling and chemical changes of peptides under acidic conditions (e.g. deamidation) the 
acid labeling should be limited to special applications [90]. 
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1.3.4 Derivatization-based techniques 
1.3.4.1 Isobaric tagging 
 Isobaric mass tagging reagents are the most widely used for derivatizing peptides in 
quantitative proteomics [96]. While the structure varies, most isobaric mass tagging reagents are 
comprised of 3 elements: (1) a mass reporter moiety with a unique number of heavy isotope (13C 
or 15N) substitutions, (2) a mass balancer moiety with complementary labels of heavy isotopes to 
balance the total mass of the reporter and balancer moieties, and (3) a reactive moiety to tag 
peptidyl amines. Two sets of amine-reactive isobaric mass tagging reagents, with a common 
reactive moiety of NHS ester, are commercially available: tandem mass tags (TMT™) [97] and 
isobaric tags for relative and absolute quantitation (iTRAQ®) [98]. They are designed to label 
primary amines (N-termini and lysine’s side chain amines) in peptides. One example of isobaric 
tags is shown in Figure 1.4. 
A set of isobaric tags has identical intact masses and chemical properties which allow for 
co-elution of differentially derivatized peptides during chromatography. Ions for the derivatized 
peptides have a common m/z and they can be co-selected by the first mass analyzer of tandem MS. 
The isobaric tags on derivatized peptide ions are then cleaved at a specific site via gas-phase 
dissociation. A set of reporter ions with unique numbers of heavy isotope labels are then detected. 
The relative signal intensities of the reporter ions are used to quantify the differentially labeled 
peptides and thus proteins. Samples that can be analyzed in a single experiment are up to 8 for 
isobaric derivatization approaches. Recently, thiol-reactive TMT™ reagents coupled with 
immuno-purification techniques are reported [99]. Reagents that are structurally similar to 
iTRAQ®/TMT™, but use less expensive deuterium labels, have the potential for further increase 
in sample throughput [100]. 
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Figure 1.4: The structure of iTRAQ® reagents. 
1.3.4.2 Mass-difference reagents 
Isotope-coded affinity tag (ICAT®), first invented in 1999, is one of the earliest chemical 
reagents introduced for quantitative proteomics at the protein level [101]. The original ICAT® 
reagents include: a thiol-specific reactive group, an isotopically modified linker, and a biotin tag 
for the enrichment of the tagged peptides. After derivatization, both heavy and light labeled 
proteins are pooled and enzymatically digested into peptides. The tagged, cysteine-containing 
peptides are then enriched with avidin affinity chromatography and quantified via MS. Cleavable 
versions of this reagent was later developed to improve the recovery of the tagged peptides [102]. 
The heavy version of the so-called cICAT reagents contain 9 13C instead of 8 2H and an acid-
cleavable biotin moiety. Insertion of an acid-labile linker greatly decreases the elution of non-
specifically bound peptides from avidin affinity materials. Isotope-coded protein labels (ICPLs) 
differentially label all of the free amino groups on proteins for relative quantitation [103]. This 
method does not require an affinity tag. 
The so-called mTRAQ® reagents are developed for introducing differential isotope labels 
in a mass different manner and are used in MRM-MS quantitation [104]. These reagents have the 
same chemical structure as those for iTRAQ® reagents, but carry redesigned stable isotope labeling 
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states. They can also be used for peptide quantitation based on the signal intensity of precursor 
ions. Reductive methylation of peptidyl amines is another commonly applied technique to 
introduce differential isotope labels to peptides. Derivatized peptides preferentially produce a1 ions 
serving as quantitation reporters [105]. These reporter ions are peptide-specific, thus lessening 
interference from co-eluting peptides with the same or similar mass. Reductive dimethylation has 
been applied to analyze low-abundance phosphopeptides [106]. 
1.3.5 Activity-based probes  
Activity-based protein profiling (ABPP) technology utilizes active site-directed chemical 
probes, combined with a range of analytical methods, for functional proteome analysis. These 
small molecules are commonly referred to as activity-based probes (ABPs). A typical structure of 
ABPs is comprised of 3 elements: (1) a reactive group for forming covalent adducts with functional 
groups at the active site of enzymes, (2) a recognizing moiety for non-covalent interactions with 
proteins, and (3) a reporting tag for detection and/or separation. Changes in the recognizing 
structural moiety can vary the reactivity and/or selectivity of the probes [107]. Small “clickable” 
handles such as an alkyne can also be incorporated as dormant reporting groups for being coupled 
with quantitation or separation tags after the in vivo reaction of the probes with living cells [108]. 
One major advantage of ABPP [109,110] over the previous techniques [111,112] is the ability to 
directly monitor active sites on a multitude of enzyme classes, and the analysis depends on the 
protein activity not on concentration or abundance. Furthermore, ABPP can be combined with 
tandem MS analysis for enriched enzyme identification. One approach, termed as activity-based 
protein profiling by multidimensional protein identification technology (ABPP-MudPIT), was 
used to profile inhibitor selectivity against hundreds of targets simultaneously via in vitro or in 
vivo reactions [113]. The integrated design of stable isotopic ABPs allows for easy implementation 
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of quantitative MS measurements in biological samples [114,115]. Another approach, termed 
isoTOP-ABPP (isotopic tandem orthogonal proteolysis-activity-based protein profiling), was used 
to quantitatively profile the intrinsic reactivity of cysteine residues across multiple proteomes by 
using a heavy isotope labeled valine and a protease-cleavable linker [116]. 
1.3.6 Sample preparation 
Generically, bottom-up proteomics sample preparation involves the solubilzation of 
proteins from the biological source, with subsequent enzymatic digestion of the proteins to 
peptides.  Each of these preparatory steps allows for unique enrichment techniques.  Figure 1.5 
summarizes the workflow and accompanying enrichment techniques. 
 
Figure 1.5: Enrichment techniques in proteome analysis. 
1.3.6.1 Pre-lysis techniques 
1.3.6.1.1 Recombinant fusion proteins 
The use of recombinant fusion proteins for protein expression determination and 
purification is a well-established technique [117]. It uses recombinant DNA technology to fuse a 
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“tag” to a protein substrate. Commonly used tags are green fluorescent protein (GFP), poly-
histidine (His-tag), glutathione s-transferase (GST), and FLAG®. A comprehensive list can be 
found in the literature [118]. Using these proteins for MS-based quantitation of their tagged-
substrates is possible. GFP is a small protein that can produce green fluorescence when illuminated 
under certain wavelengths. This qualitative measurement has been transcended into a quantitative 
measurement in MS by introducing SILAC [119] or an amine-specific isotope tag termed iTAG 
[120]. The inherit fluorescence of GFP was also quantitatively measured and protein binding 
partners were determined with shotgun proteomics [121]. All of these measurements exploit 
immunoprecipitation (IP) of the GFP fusion protein. There are commercial products (e.g. GFP-
Trap®) that recognize GFP and pull down protein complexes. His-tag can also be used similarly. 
The original use of recombinant polyhistidine protein with immobilized metal ion affinity 
chromatography (IMAC) was described in 1988 [122]. This was applied to purify proteins by 
adding the small tag. It can also be used for the same purpose, but with subsequent MS analysis.  
There are, however, few quantitative examples of this [123]. 
1.3.6.1.2 Biotin tagging at specific sites 
Chemical derivatization of proteins can be performed at the cellular level. There are many 
forms of chemical “tagging,” but biotin tagging is commonly used. Biotin has a very low 
dissociation rate (KD≈10-15M) from avidin [124]. This kinetic property is the basis for enrichment 
of biotin-tagged proteins with avidin on a solid support (e.g. agarose beads). The non-bound 
proteins can then be washed away, and the bound proteins eluted. By functionalizing the biotin 
moiety with reactive groups, biotin tagging can be performed to specific sites on proteins. Two 
examples that use functionalized biotin in quantitative proteomics are experiments measuring 
lysine exposure on a peptide [125] and cell surface protein expression [126]. 
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1.3.6.2 Protein-level enrichment 
1.3.6.2.1 Antibody-based enrichment 
Co-immunoprecipitation (co-IP) is a common technique to enrich protein interaction 
complexes. This method uses an antibody to bind a known protein, which in turn has known or 
unknown binding partners. Shotgun proteomics is then performed to determine the enriched 
proteins. Quantitative MS is used to validate bound proteins and measure binding stoichiometry 
for proteins in the complexes prepared via IP [127,128]. Quantitation approaches used include 
SILAM [129], label-free [130], and AQUA peptides with a normalization step [131]. 
1.3.6.2.2 Immunodepletion 
Proteome samples often have very large ranges in protein concentration. Dominant, high 
abundance proteins can compromise the analysis of minor protein components. For instance, 
plasma is composed of a complex mixture of proteins and albumin and immunoglobulin G (IgG) 
compose over 60% of the total protein amount in plasma [132]. These abundant proteins can make 
the analysis of medium to low abundance proteins very difficult [133,134]. Depletion of these and 
several other abundant proteins allow for in-depth analysis of low abundance ones. There are many 
commercial products for protein immunodepletion. Applications of the products are reported for a 
Seppro® column in a label-free method [135]. Seppro® column in a SILAP method [136], a Hu-6 
Multiple Affinity Removal System (MARS) kit in an iTRAQ® method [137], and a Hu-6 MARS 
kit in another iTRAQ®-based method [138]. Caution should be observed if a low abundance 
protein has affinity to a high abundance protein because it can be co-depleted. 
1.3.6.2.3 Techniques based on PTMs 
PTMs of proteins enable many important functions in organisms [139]. Proteins with PTMs 
can be enriched in a variety of ways: antibody-based, chemical derivatization, and ionic 
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interaction-based [89]. Antibodies that are highly specific to a particular PTM site greatly help 
functional assays. Antibodies that preferably bind a class of PTM, e.g. proteins carrying 
phosphotyrosine residues, make possible the in-depth quantitative proteomic analysis of these 
proteins. The sub-stoichiometric nature of PTMs yields a low concentration of modified proteins. 
Enrichment of these proteins allows for improved analysis. 
1.3.6.3 Peptide-level enrichment 
1.3.6.3.1 Stable isotope standards and capture by anti-peptide antibodies (SISCAPA) 
Immunoenrichment can be applied at the peptide level, particularly in the SISCAPA 
method [140]. Target peptides together with their stable isotope labeled counterparts (used as 
quantitation references) are enriched by antibodies that are developed against antigens with almost 
the same sequences. The antibodies are often covalently attached to magnetic beads for sample 
cleanup. This technique boasts an improved limit of quantitation and increased inter-laboratory 
reproducibility [141]. 
1.3.6.3.2 Techniques based on PTMs 
Many of the techniques used to enrich PTMs at the protein level are applicable at the 
peptide level. A popular method for enrichment of phosphopeptides is to use an immobilized metal 
affinity column. The molecular basis for the enrichment is the phosphate affinity to transition metal 
ions, such as, copper, nickel, cobalt, iron, aluminum, gallium, and zinc [142]. A comprehensive 
source for phosphopetide enrichment strategies can be found in a recent review [143]. Lectin-
based chromatography is used to enrich for glycopeptides [144]. Lectins are proteins that have an 
affinity for carbohydrates. With multiple available enrichment options, choosing a right one for 
the experiment is important. For determining which proteins have a certain PTM, protein-level 
enrichment can be performed. However, if a type of PTM is of interest, then peptide-level 
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enrichment will yield less sample complexity. The use of multiple antibodies to enrich for multiple 
PTMs simultaneously has led to the development of PTMScan® technology [145]. A monoclonal 
antibody specific to the diglycine tag on lysine residues has also been used to enrich ubiquitinated 
tryptic peptides [146]. 
1.3.7 Liquid chromatography 
In shotgun (bottom-up) proteomics workflows, proteins are digested by proteases and the 
resulting peptides are separated by LC before MS analysis [147]. With the rapid advancement in 
LC and MS instrumentation, LC-based proteomics overwhelms the 2-DE-based approaches. The 
shotgun proteomics pipeline can provide improved throughput, sensitive protein profiling, and 
accurate protein quantitation. When working with complex samples, such as human serum, the 
bottom-up approach produces thousands of peptides with very different abundances and some of 
the peptides have similar m/z ratios. This requires high resolution separation of peptides prior to 
MS analysis. LC reduces ion suppression of co-eluting peptides during ionization and increases 
the likelihood of detecting low abundance peptides [147]. Different LC methods have been 
developed for proteomic analyses such as reversed phase (RP), ion-exchange (IEX), and 
hydrophilic interactions chromatography (HILIC). RP separations are the dominant choice due to 
the very high resolving power and electrospray ionization (ESI) MS-friendly solvents. 
1.3.7.1 Common separation modes 
1.3.7.1.1 RP chromatography 
Introduced in 1976, RP chromatography is the mostly used approach for peptide separation 
[147,148]. Peptides are separated in a RP column upon partitioning between the hydrophobic 
stationary phase and the mobile phase. Peptides are loaded onto the column using low organic 
solvent, allowing for initial desalting and concentration of the sample. Separation and elution of 
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the peptides occur by increasing the percentage of organic solvent in the mobile phase; commonly 
used solvents are acetonitrile and methanol due to their appropriate solvent strength, volatility, 
viscosity, and MS compatibility. Acidic modifiers help improve resolution of RP chromatography 
of peptides by acting as ion pairing agents for positively charged groups on peptides. RP stationary 
phases are mostly silica-based C18 resin and acid additives help improve peak resolution by 
keeping residual silanol groups protonated. From a separation perspective, trifluoroacetic acid 
(TFA) has a higher hydrophobicity and enables narrower peaks than other acids like acetic acid 
and formic acid (FA). FA, however, is the common choice for online use with ESI MS to minimize 
ion suppression. 
1.3.7.1.2 IEX chromatography 
 Peptide separation in IEX chromatography is based on electrostatic interactions between 
charged groups on the peptides and the charged stationary phase. The mobile phase can be a buffer 
whose salt strength changes during separation. Separation can also be achieved by changing the 
pH value of the mobile phase to neutralize the charge of the analytes and/or stationary phase. IEX 
chromatography is classified into cation exchange (CX) and anion exchange (AX) chromatography 
[149]. CX is divided into 2 categories: strong cation exchange (SCX) and weak cation exchange 
(WCX). SCX chromatography utilizes strong acids such as sulfonic acid derivatives and is the 
second mostly used chromatographic method in LC-based proteomic analysis. WCX, on the other 
hand, is restricted to a smaller pH range and its application is limited [147,150,151]. 
1.3.7.1.3 HILIC 
HILIC uses a polar stationary phase to separate proteins and peptides. Samples are loaded 
onto a column using a low aqueous mobile phase and are eluted by increasing the water content of 
the mobile phase [152]. HILIC is very suitable for separation of polar species such as sialic acid-
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containing glycopeptides which have limited retention on most RP materials [153]. A variant of 
HILIC is electrostatic repulsion-hydrophobic interactions chromatography (ERLIC) and it utilizes 
ion-exchange stationary phase and a high organic mobile phase [152,154]. 
1.3.7.2 Multidimensional LC strategies 
When working with complex peptide mixtures like a proteome digest, multiple separations 
help with analysis of minor components in the mixture. Coupling two different modes of LC results 
in the improved separation of peptides and thus reduced number of co-eluting peptides for MS 
analysis. To utilize the maximum separation space afforded by multidimensional LC, 
orthogonality of different chromatography modes which separate peptides based on largely 
different properties is important [155]. For example, SCX-RP is more orthogonal than a RP-RP 
combination. Multidimensional LC can be achieved by coupling 2 or more 1-D techniques either 
online or offline [147]. LC separation of peptides that utilizes different protonation states of 
peptides at low and high pH in a RP-RP combination is also attractive. This combination avoids 
the use of MS-unfriendly salts used in SCX-RP separations [156,157]. Figure 1.6 illustrates the 
first MudPIT system for the direct analysis of large protein complexes [158,159]. 
Figure 1.6: Online 2-D chromatography systems coupled with MS/MS.i 
 
                                                          
i Figure by Reza Nemati. McShane, A. J.; Farrokhi, V.; Nemati, R.; Li, S.; Yao, X. An Overview of Quantitative 
Proteomic Approaches. Comprehensive Analytical Chemistry, Oxford, UK; Elsevier, 2014; p. 111-135. 
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1.3.7.3 LC using new separation media 
Ultra performance liquid chromatography (UPLC) is an important advancement in 
chromatography due to the significantly improved speed, resolution, and sensitivity [160]. UPLC 
typically uses separation media with a particle size less than 2.0 μm [161,162]. UPLC systems 
operate under very high pressure to accommodate the use of small particles. This technology 
allows for faster flow rates, while maintaining the separation efficiency and thus increasing the 
sample throughput of analysis [161,163]. 
As an alternative to wholly porous sub-2 μm particles, 1.7 μm fused-core particles 
surrounded by a 0.5 µm porous silica layer with 90 Å pores, have emerged. In a comparative study, 
substantially lower back pressure was reported when the fused core particles were used. This 
allowed for columns to be coupled in series which increased the peak efficiency up to 92750 plates 
[164]. Wider-pore fused-core particles have an average pore diameter of 160 Å. The wider-pore 
particles are particularly useful for increased sample loading and the rapid separation of peptides 
using volatile mobile phases [165]. 
1.3.7.4 Nanoscale LC 
Nanoscale liquid chromatography (nano-LC) using RP separation materials is the default 
choice for LC-MS of peptides from proteome digests. Nano-LC has excellent sensitivity using 50-
100 μm diameter columns and 200-300 nL/min flow rates [166]. An all-inclusive definition for 
nano-LC is a LC that separates nanoliter amounts of sample, with nanoliter amounts of mobile 
phase, and yields detection limits in the range of nanograms per milliliter [167]. 
1.3.7.5 GeLC method 
In this method, proteins in cell lysates or complex mixtures are typically first separated by 
SDS PAGE. Followed by in-gel enzymatic digestion of the separated proteins, the resulting 
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peptides are extracted for 1-D or multidimensional LC separation before MS analysis. This 
approach takes advantage of high resolution SDS-PAGE for proteins under denaturing condition, 
thus reducing the sample complexity at the protein level. LC separations further reduce sample 
complexity at the peptide level. Also, with staining gel bands, it’s possible to separate gel pieces 
containing high abundance proteins [158]. This technique can be applied to 2-D gels as well [168]. 
1.3.8 Software 
Software tools are a must for proteome analysis, considering the massive data produced. 
Data analysis typically starts with peptide identification with a set of tandem mass spectra and 
database search engines, such as Mascot [169], Sequest [170], and X!Tandem [171]. Extracted ion 
chromatograms (XIC) can be reconstructed and the ratios of signal intensities estimated from either 
peak heights or areas for quantitative analysis. Statistical analysis of results is essential, including 
assignment of significant scores, normalization of peptide abundances, and statistical evaluation 
of quantitation results, as well as function and location of proteins. Significant development of 
MS-based proteomic technologies in the past decade encouraged the concurrent advance in data 
analysis tools [172-174]. Further reading on bioinformatics and other computing concerns for 
proteomics can be found elsewhere in this book. 
1.3.9 Analyte multiplexing and sample throughput 
Contemporary proteomics demands high-throughput and multiplexed analytical strategies 
and platforms. In the early stages of the biomarker discovery pipeline, for instance, multiplexed 
analysis of peptides from thousands of proteins in a few samples is required. However, further 
down the pipeline there is a shift towards high-throughput analysis because the number of samples 
increases dramatically and number of peptides or analytes decreases [175]. MRM MS methods 
currently dominate MS-based high-throughput quantitative proteomics [176,177]. Efforts in 
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developing MRM approaches to perform both multiplexed and high throughput analysis via either 
immuno-enrichment [178] or ultra-throughput multiple reaction monitoring (UMRM) [179] are 
reported. New MS strategies to improve the sample throughput of proteomic analysis are emerging 
using recently available mass spectrometers. 
1.4 Conclusion 
The field of proteomics has evolved significantly thanks to collective efforts from 
practitioners with eclectic backgrounds. Technological advances in every step of the proteome 
analysis pipeline, from sample preparation to MS analysis to protein identification and quantitation 
to protein functional denotation, have significantly reduced the induction period of initial learning 
and encouraged the widespread adaption of proteomics. Fruitful applications continuously emerge 
in the study of biomarkers, disease, medicine, food and plants, and the environment, just to name 
a few. The inherit sample complexity and diversity still present both technical challenges and 
opportunities for in-depth analysis of the entire proteome. 
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2.1 Introduction 
For cystic fibrosis (CF), the most common autosomal recessive genetic disease, there is a 
recent paradigm shift from treating disease symptoms toward developing drugs that repair 
fundamental defects in the anion channel of cystic fibrosis transmembrane conductance regulator 
(CFTR) [1-3]. CFTR is a member of the ATP-binding cassette (ABC) transporter superfamily and 
functions as a cAMP-dependent, protein kinase-activated Cl− channel in the plasma membrane 
(PM). It has five structural domains: two transmembrane domains (TMD1 and TMD2), two 
nucleotide-binding domains (NBD1 and NBD2), and a unique regulatory domain (RD). Deletion 
of a phenylalanine at position 508 (F508del) is the most frequent mutation, accounting for ~90% 
of the CF population. The F508del mutation is located in NBD1, putatively interfacing with TMDs, 
and impairs coupled domain folding, PM expression, ion channel function, and protein stability 
[4,5]. The misfolded mutant is retained inside cells at the endoplasmic reticulum (ER), and is 
degraded by the proteasome [6]. Evidence suggests that, during biosynthesis and trafficking of 
CFTR, different domains of the protein interact with various chaperone systems, facilitating the 
maturation of wild-type CFTR (wtCFTR) and the recognition of F508del mutant. Thus, F508del 
expression in the apical PM is minimal; consequently, F508del CF patients do not have sufficient 
CFTR channel activity in epithelial cells in their airways, intestine, pancreas, sweat ducts, testes, 
and other fluid-transporting tissues [7,8].  
Two major categories of new CFTR modulator drugs are currently under extensive clinical 
and research investigations [9]; corrector drugs repair the biogenesis, trafficking, and ultimately 
the apical PM expression of the protein and potentiator drugs enable the channel function of 
mutant CFTR proteins in the PM. Corrector drugs like VX-809 (Lumacaftor) repair folding and 
trafficking of CFTR mutants and enhance the apical PM expression of F508del [2,10,11]. The 
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rescue of PM expression of mutant CFTR, like F508del, by corrector drugs is the first step into 
restoring Cl- channel activity.  However, VX-809 has limited clinical benefit for F508del CF 
patients, and its mechanism of action has yet to be fully understood [2,12].  In addition, it is 
generally agreed that the first generation of CF drugs has reached an apparent therapeutic ceiling 
[2,3,13-16]. In-depth analysis of how current investigational drugs work will gain mechanistic 
insights for developing future CF medicines. These studies would be greatly enhanced by accurate 
measurements of CFTR and its mutants in cells, especially in the PM where the protein performs 
its vital ion channel function.  
Difficulties in the analysis of CFTR are among the major challenges for molecular 
investigations of CF drug action. CFTR is a large, glycosylated, multi-domain, and low abundance 
integral membrane protein. In order to evaluate the efficacy of drug compounds, efficient methods 
are needed to detect and quantify changes in the PM CFTR expression. Historically, western blot 
analysis of CFTR has been the central CFTR quantitation method in CF research [17]; newly-
developed antibodies have greatly improved the sensitivity of the method [18]. However, the 
reproducibility, precision, accuracy, and robustness of the method are less than ideal, only 
providing semi-quantitative measurements, with a relatively large coefficient of variance and a 
narrow dynamic range. Furthermore, CFTR aggregates and degrades during sample preparations, 
leading to large measurement variations. These critical problems with membrane proteins present 
major, intrinsic challenges for quantitative analysis [19-21]. Other methods for quantifying surface 
expression of CFTR require engineered cells [e.g. green fluorescent (GFP) fusion proteins] and 
are not directly applicable to primary cells, which are better systems for testing new experimental 
drugs.  
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Technology innovations, from genomics [22] to proteomics [23,24], have played important 
roles in advancing CF research and therapy. We have developed the first quantitative method to 
mitigate the intrinsic analytical problems with full-length CFTR and use CFTR signature peptides 
as measurement surrogates [25]. CFTR is digested into peptides that are relatively easy to prepare 
for mass spectrometry (MS) quantitation. CFTR quantified in this work ranges from a few tens of 
picograms to low nanograms per million baby hamster kidney cells overexpressing wtCFTR 
(BHK-wtCFTR) or human colorectal adenocarcinoma cells (HT-29) [25]. A signature peptide is 
selected for quantitation by a method of liquid chromatography—stable isotope dilution—multiple 
reaction monitoring MS (LC-SID-MRM MS). It is the method of choice for quantifying target 
proteins in complex biomatrices [26-28], which is regarded as the MS version of western blot 
analysis, and has comparable sensitivity but superior specificity. MRM MS monitors gas-phase 
dissociation reactions of target analytes, which requires sequential detection of an analyte 
precursor ion as the reactant followed by one or several analyte fragment ions as the products; 
therefore, it is highly specific and can be applied to complex samples with minimal component 
separation. The sensitivity and specificity afforded by MRM MS method lifts the dependence on 
high-quality antibodies for conventional immunoassays of protein targets like CFTR [18].  
However, later addition of peptide quantitation reference standards cannot be used to 
normalize (1) differential sample loss during CFTR enrichment—CFTR has low concentration in 
the PM and it is essential to enrich the protein to obtain the needed quantitation limit and (2) 
variations in proteolytic digestion of CFTR—membrane proteins are difficult to digest completely 
[29]. Thus peptide-level quantitation reference standards are less than ideal for the absolute 
quantitation of CFTR. More reliable absolute quantitation of PM CFTR will enable accurate and 
precise sample-to-sample, day-to-day, analyst-to-analyst, and lab-to-lab comparison of results, 
 54 
 
similar to that shown for LC-SID-MRM MS quantitation of plasma proteins [26], and greatly 
facilitating the development of new CF drugs. Herein we report a general workflow (Scheme 2.1) 
for the enrichment and absolute quantitation of large, low-abundance CFTR (and other membrane 
proteins) in the apical PM (broadly referred to as the fraction of PM that is not in contact with 
culture support and thus is accessible to cell surface biotinylation) of BHK-wtCFTR and CFBE 
cells. With a variation of this method, CFTR turnover in the apical PM of BHK-wtCFTR cells is 
measured for the first time without using radioisotopes. 
Scheme 2.1: Tandem enrichment of 
CFTR in the PM and workflow for 
targeted proteomic quantitation of the 
absolute expression. 
 
 
 
 
 
 
 
 
2.2 Experimental 
2.2.1 Materials 
Urea, Tris base, iodoacetamide, acrylamide/bis-acrylamide solution (40%, 29:1), 
N,N,N',N'-tetramethylethylenediamine, L-leucine, L-lysine, L-arginine, methotrexate, 
doxycycline, protease inhibitor cocktail, sodium orthovanadate, 1 M tris-HCl buffer solution,  
phosphate buffer saline (PBS, 10x pH 7.4), Triton X-100, and the anhydrides were purchased from 
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Sigma-Aldrich, Inc. (St. Louis, MO).  Pierce cell surface protein isolation kit, dithioerythritol 
(DTE), β-mercaptoethanol (β-ME), iodoacetamide, trifluoroacetic acid (TFA), ammonium 
bicarbonate, ammonium persulfate, formic acid, and HPLC grade acetonitrile were purchased from 
Fisher Scientific (Fair Lawn, NJ).  The peptide CFTR01 was synthesized by AnaSpec (San Jose, 
CA) or Peptide 2.0 (Chantilly, VA).  Isotopic CFTR01 peptide (NSILTET[L-13C6
15N]HR was 
synthesized by Cambridge Research Biochemicals (Cleveland, UK). 18O-Water (>97%) was 
purchased from Cambridge Isotope Laboratories (Andover, MA) or given as a gift from Olinax 
(Hamilton, ON, Canada). Water was obtained from a Milli-Q ultrapure water purification system 
(Millipore, Billerica, MA).  Proteomics grade recombinant trypsin was purchased from Roche 
Applied Science (Indianapolis, IN).  Human embryonic kidney cell line (HEK293F) stably 
transfected with fused cDNA for wtCFTR and GFP (HEK293F-D042-JK)—HEK293F-
wtCFTR—was a gift from Dr. John C. Kappes (University of Alabama at Birmingham). A cystic 
fibrosis bronchial-derived cell line complimented with a 4.7 Kb wild type CFTR cDNA (CFBE 
41o-/pCEP–CFTR N 4.7 kb) and a cystic fibrosis bronchial-derived cell line complimented with a 
4.7 Kb F508del CFTR cDNA (CFBE 41o-/pCEP –CFTR F508del 4.7 kb) were from Dr. Dieter 
Gruenert (University of California at San Francisco) [30]. The HT-29 cell line was purchased from 
American Type Culture Collection (Manassas, VA). Purified full-length CFTR samples were gifts 
from Dr. L. J. DeLucas (University of Alabama at Birmingham) and Dr. J. He (Accelagen, San 
Diego, CA). Purification of the later full-length CFTR sample was performed according to a 
procedure developed by Dr. J. R. Riordan at the University of North Carolina, Chapel Hill. The 
absolute concentration of this highly-purified CFTR sample was obtained by amino acid analysis 
and this sample was used as the reference standard to quantify stable isotope labeled CFTR 
samples prepared in-house (see the following section). Amino acid analysis for the highly-purified, 
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native CFTR was performed at the Keck Biotechnology Resource Laboratory at Yale University. 
DMEM, Ham’s F-12, DME/Low media deficient in L-arginine, L-leucine and L-lysine, and fetal 
bovine serum were purchased from Thermo Scientific HyClone (Logan, UT). Dialyzed fetal 
bovine serum was purchased from Life Technologies (Thermo, Carlsbad, CA).   
2.2.2 Cell culture and preparation of protein quantitation standard 
BHK-wtCFTR cells were cultured in DMEM/Ham’s F-12 with 550 µM methotrexate and 
10% of each of the following reagents: fetal bovine serum, pen-strep, non-essential amino acids, 
and sodium pyruvate.  The heavy isotope labeled, full-length CFTR was obtained, by the method 
of stable isotope labeling by amino acids in cell culture (SILAC) [31], from BHK-wtCFTR cells 
cultured in DME/Low deficient in L-lysine, L-leucine, and L-arginine supplemented with 550 µM 
methotrexate, 0.4 mM L-arginine•HCl, 0.8 mM L-lysine•HCl, 0.8 mM L-leucine-1,2-13C 
(Cambridge Isotopes, Andover, MA), and 10% of dialyzed fetal bovine serum.  Cells grown in this 
labeled media were allowed at least 7-8 doublings prior to harvesting.  CFBE 41o-/pCEP–CFTR 
N 4.7 kb  and CFBE 41o-/pCEP–CFTR F508del 4.7 kb were grown in MEM medium with 0.3 g/L 
L-Glutamine, 1 g/L Glucose, 2.2 g/L NaHCO3, 10% of fetal bovine serum, 20 mM sodium 
pyruvate, 10,000 mcg/ml streptomycin, and 10,000 units/ml penicillin. The CFBE cells were 
grown in plates or snapwell filters (Sigma-Aldrich, St. Louis, MO) that were coated with human 
fibronectin (Fisher Scientific, Fair Lawn, NJ). The HEK293F-wtCFTR cells stably transfected 
with wtCFTR-GFP fused cDNA were cultured using DMEM with 10% fetal bovine serum and 
doxycycline added at 0, 0.25, 0.75, or 1.00 µg/mL the night before cell harvesting.  
2.2.3 Cell-surface biotinylation and cell lysate fractionation 
Surface biotinylation [25,32] was performed on cells using the surface protein isolation kit 
from Pierce, following the manufacturer’s instructions. Briefly, cells were first labeled with a thiol-
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cleavable, amine-reactive biotinylation reagent [sulfosuccinimidyl-2-(biotinamido)ethyl-1,3-
dithiopropionate (sulfo-NHS-SS-biotin)] and quenched. The biotinylated cells were dislodged by 
trypsinization or scraping from the plates or filters, and subsequently lysed with buffer. The lysis 
buffer (800 μL) containing 1% (v/v) Triton X-100, 150 mM NaCl, 20 mM Tris-HCl at pH 7.2, and 
1% (v/v) protease inhibitors was used for the lysis of 12-14 million BHK-wtCFTR cells or 6-8 
million CFBE cells.  The labeled proteins were captured on avidin agarose and released using 
Triton X-100 buffer containing 50 mM dithiothreitol (DTT). 
2.2.4 Gel-based electrophoretic enrichment (GEE) 
Gel electrophoresis was performed using a resolving gel consisting of 8% acrylamide and 
0.2% bisacrylamide. BioRad glass plates with 1.0 mm spacer plates and 10-well comb were used 
for analysis of overexpressed CFTR; a single well allowing for 20 µL loading volume was 
sufficient for analysis of overexpressed CFTR in about 8 µg of total biotinylated protein. For 
endogenous CFTR, 1.5 mm spacer plates and 2-well comb consisting of 1 preparative well for 
sample loading (680 µL, 500 µg of total biotinylated proteins) and 1 well for loading the standard 
molecular weight protein marker or purified CFTR were used. For the turnover study, 1.5 mm 
spacer plates and a 5-well (120 µL) comb were used.  CFTR samples were mixed with Laemmli 
sample buffer and incubated at 30oC for 30 mins. Gel electrophoresis was carried out at 200 V 
constant voltage for 45 min or until the dye front reached the bottom of the gel. 
2.2.5 Digestion 
Gel pieces at the interface between the resolving and the stacking gels (~1 mm3) were 
excised for further sample preparation. Gel pieces were washed (25 mM ammonium bicarbonate 
in H2O/acetonitrile), reduced (10 mM DTE), and alkylated (20 mM iodoacetamide) before 
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trypsinization (20 ng/µL). The resulting digestion solution was dried via SpeedVac (Savant, 
Farmingdale, NY) and overnight lyophilization (Labconco, Kansas City, MO). 
2.2.6 LC-SID-MRM MS 
The optimization and data analysis of this work was assisted by the Skyline software[33].  
The preparation of stable isotope reference 18O(Δ4)-CFTR01 and LC-SID-MRM MS quantitation 
were performed following previously reported procedures [25]. Some exceptions were those 
experiments where CFTR protein quantitation was accomplished in CFBE and BHK-wtCFTR 
cells. In those cases, an Eksigent NanoLC-Ultra 2D+ (Redwood City, CA) was used at a flow rate 
of 400 nL/min with a self-pack Picofrit column (New Objective, Woburn, MA) filled with 2.7 µM 
diameter, 160Ǻ pore Halo resin (MacMod, Chadds Ford, PA) and the length of resin bed was 
around 15 cm. Solvent A was composed of 98.8% H2O, 1.0% acetonitrile, and 0.2% formic acid 
(v/v) and solvent B’s composition was 98.8% acetonitrile, 1.0% water, and 0.2% formic acid (v/v). 
A typical running gradient was 1%B at 0 min → 3%B at 5 min → 30%B at 50 min → 80%B at 
59 min → 90%B at 69 min →1%B at 80 min, with 10 min equilibration. Samples were loaded on 
the trap column at flow rate of 4 μL/min at 1% solvent B for 10 min.  A triple quadrupole mass 
spectrometer was used, 4000 QTrap from ABSCIEX (Foster City, CA). Transitions for the native 
and stable isotope labeled peptides are summarized in Table 2.1. 
2.2.7 Peptide derivatization and ultrathroughput multiple reaction monitoring (uMRM) MS 
[34] 
Following in-gel digestion of the HEK293F-wtCFTR cell lysate the N-termini of the 
peptide mixtures were derivatized with anhydrides (acetic, propionic, butyric, valeric, or succinic 
anhydride). To each sample were added 70 µL of acetonitrile, 70 µL of 1M ammonium 
bicarbonate, and 10 µL of the appropriate anhydride, and samples were incubated on ice for 1 h. 
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Following the incubation, another addition of 100 µL of acetonitrile, 100 µL of 1M ammonium 
bicarbonate, and 10 µL of the appropriate anhydrate were added, samples were incubated on ice 
for an additional 2 h. After the chemical derivatization, the modified peptides were dried and 
desalted using hydrophilic-lipophilic-balanced sorbent (HLB, Oasis®) and lyophilized.  The 
resulting 5 derivatized digests were combined for a single uMRM MS experiment.  
2.2.8 PM CFTR turnover study 
In a typical experiment, BHK-wtCFTR cells for each time point were grown in triplicate 
in non-isotopic media.  At time zero, the media was aspirated, the cells were washed twice with 
PBS, and isotopically labeled media was added as follows: (1) BHK-wtCFTR media minus 
arginine, leucine, and lysine and supplemented with 0.4 mM L-arginine•HCl, 0.8 mM L-
lysine•HCl, 0.8 mM L-leucine-1,2-13C2= or (2) BHK-wtCFTR media minus arginine, leucine, and 
lysine and supplemented with 0.4 mM L-arginine-13C6•HCl (Cambridge Isotopes, Andover, MA), 
0.8 mM L-lysine-13C6
15N2•HCl (Cambridge Isotopes, Andover, MA) and 0.8 mM L-leucine.  At 
the appropriate time, the cells were biotinylated, combined, and fractionated as previously detailed. 
After protein digestion, signature peptides for native and stable isotope labeled CFTR were 
quantified by LC-SID-MRM MS.   
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Table 2.1: CFTR signature peptides and isotopic counterparts with respective transitions for LC-SID-MRM MS analysis. “Δx” denotes 
a mass increase; i.e., Δ4 means a mass increase of 4 Da for the isotope-labeled peptide compared with the native counterpart.
Peptide  Origin Sequence Transition Type 
CFTR01 Native NSILTETLHR 
[M+2H]2+ → y7, y6, y5 
L(Δ4)-CFTR01 SILAC NSI[L-1,2-13C2]TET[L-1,2-13C2]HR 
R(Δ6)-CFTR01 SILAC NSILTETLH[R-13C6] 
18O(Δ4)-CFTR01 Synthetic, 18O-Labeling NSILT[E-18O2]TLH[R-18O2] 
L(Δ7)-CFTR01 Synthetic NSILTET[L-13C615N]HR 
CFTR02 Native LSLVPDSEQGEAILPR 
[M+2H]2+ → y12, y10, y9 L(Δ6)-CFTR02 SILAC [L-1,2-13C2]S[L-1,2-13C2]VPDSEQGEAI[L-1,2-13C2]PR 
R(Δ6)-CFTR02 SILAC LSLVPDSEQGEAILP[R-13C6] 
CFTR03 Native ISVISTGPTLQAR 
[M+2H]2+ → y8, y7, y6 
R(Δ6)-CFTR03 SILAC ISVISTGPTLQA[R-13C6] 
CFTR04 Native NSILNPINSIR 
[M+2H]2+ → y8, y7, y6 
R(Δ6)-CFTR04 SILAC NSILNPINSI[R-13C6] 
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2.3 Results and discussion 
2.3.1 A general strategy of cell-surface biotinylation and GEE for the tandem enrichment of 
large and low-abundance PM proteins  
Membrane proteins are critical for cells to communicate with the extra-cellular 
environment. Receptors and transporters in the PM thus form the most dominant protein class for 
developing drugs to treat human disease [35]. These membrane proteins are typically large, 
hydrophobic, and low in abundance. Preparation of membrane proteins and proteome samples is a 
major analytical bottleneck in analysis [19,20]. We have thus designed a novel, broadly-applicable 
workflow to enrich low-abundance, large membrane proteins by sequential use of (1) the 
established method of cell surface biotinylation and (2) a method of gel electrophoretic enrichment 
(GEE), which is a variant of gel electrophoresis (Scheme 2.1). 
GEE makes special use of sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) for separation of protein mixtures. In the GEE method, non-gradient gels are used 
for protein fractionation and the gel compositions are formulated in such a way that proteins larger 
than a minimum molecular weight do not migrate appreciably in the resolving gel. It is a simple 
but effective approach for enriching high-molecular weight proteins (e.g. >150 kDa) in a complex 
mixture (Figure 2.1). For enriching CFTR, the composition for the resolving gel is 8% acrylamide 
and 0.2% bisacrylamide. This composition slows the migration of large proteins and limits their 
location to the interface region of the resolving and stacking gel while allowing for the 
electrophoretic migration of smaller proteins. With or without gel staining, a protein fraction with 
a predictable lower cutoff of molecular weight (i.e., proteins that have molecular weights higher 
than a designed value) can be reproducibly sampled by excising gel slices at a fixed location near 
the interface (Figure 2.1) for subsequent in-gel digestion and MS analysis. 
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Figure 2.1: Gel electrophoretic enrichment (GEE) of large membrane proteins. The large proteins 
are sampled by slicing the gel piece at the interface of the stacking gel and the resolving gel (A). 
Samples loaded were: 1, protein ladder; 2, β-galactosidase; 3, 500 ng of CFTR; 4, 1 μg of CFTR; 
5, 10 μg of BHK-wtCFTR biotinylated fraction; 6, 1 μg of BHK-wtCFTR biotinylated fraction; 7, 
30 μg of BHK-wtCFTR Triton X-100 extract; and 8, 3 μg of BHK-wtCFTR Triton X-100 extract. 
The gel piece (red box) was cut for in-gel digestion (B; other bands were low-molecular weight 
membrane proteins removed by GEE), and the resulting peptides were extracted (C) and analyzed 
by LC-SID-MRM MS (D).i 
 
Expression of CFTR in the PM is low, and the tandem enrichment strategy made CFTR 
quantitation possible by LC-SID-MRM MS [36], without using antibody enrichment of the protein 
[25]; this is due to both the increase in CFTR concentration and the decrease in the sample 
complexity for MS quantitation. Mutant CFTR proteins, even after therapeutic intervention, exist 
in even lower amounts in the PM; thus, enrichment of PM CFTR is necessary for quantifying the 
protein by MS. A study was performed to compare LC-SID-MRM MS quantitation of CFTR 
signature peptides prepared by the tandem enrichment workflow with those in the direct digestion 
                                                          
i Work and figure by Alexis Ramos. McShane, A. J.; Bajrami, B.; Ramos, A. A.; Diego-Limpin, P. A.; Farrokhi, V.; 
Coutermarsh, B. A.; Stanton, B. A.; Jensen, T.; Riordan, J. R.; Wetmore, D.; Joseloff, E.; Yao, X. Targeted 
Proteomic Quantitation of the Absolute Expression and Turnover of Cystic Fibrosis Transmembrane Conductance 
Regulator in the Apical Plasma Membrane. J. Proteome Res. 2014, 13, 4676-4685. 
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mixture of the PM subproteome prepared by surface biotinylation and avidin pull-down for HT-
29 cells. Only the former workflow resulted in confident quantitation, and the measurement gave 
40 fmol of apical PM CFTR per million cells, equivalent to 23,000 molecules per cell (Figures 
2.1 and 2.2). It should be noted that this amount is based on a peptide quantitation reference 
standard [18O(Δ4)-CFTR01] [25] and thus represents the lower range of  PM CFTR in HT-29 cells 
(see later section for discussion on protein vs. peptide quantitation reference standards). Although 
the GEE method by itself can be used for preparing CFTR signature peptides from various protein 
(mixture) samples containing CFTR, it is necessary to have the surface biotinylation enrichment 
in the workflow. Thus, only matured full-length CFTR (commonly referred to as the “Band C” 
[37] by the CF research and clinical community) in the PM is sampled for quantitation; the GEE 
method does not separate the non-glycosylated CFTR (commonly referred to as the “Band B”37) 
from that which is fully matured. 
 
Figure 2.2: It is essential to use a 
tandem enrichment strategy for 
preparing PM CFTR samples. MRM 
ion chromatograms are shown for the 
native signature peptide (solid line) 
and the spiked stable isotope 
reference peptide (dotted line) of 
digests of HT-29 cell lysate prepared 
by surface biotinylation and GEE (A) 
and surface biotinylation only (B).i  
 
Another analytical advantage for the GEE method is compatibility with various 
solubilizing reagents used for preparing samples containing CFTR. To enhance solubilization of 
                                                          
i Work and figure by Alexis Ramos. McShane, A. J.; Bajrami, B.; Ramos, A. A.; Diego-Limpin, P. A.; Farrokhi, V.; 
Coutermarsh, B. A.; Stanton, B. A.; Jensen, T.; Riordan, J. R.; Wetmore, D.; Joseloff, E.; Yao, X. Targeted 
Proteomic Quantitation of the Absolute Expression and Turnover of Cystic Fibrosis Transmembrane Conductance 
Regulator in the Apical Plasma Membrane. J. Proteome Res. 2014, 13, 4676-4685. 
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membrane proteins, SDS and other detergents are used in the extraction and digestion buffers. 
However, the presence of detergents can interfere with protease activity during protein digestion, 
and can also affect chromatographic separation and suppress ionization of resulting peptides. 
Although the detergents can be removed after digestion, cleanup of detergent-containing peptide 
mixtures can cause significant sample loss and has varying efficiencies. In contrast, during the gel-
based sample preparations detergents and other interfering reagents are removed by extensive 
washing before digestion. It has been reported that protein mixtures can be concentrated to a thin 
band after a short-running SDS-PAGE; the main purpose of this practice has been the removal of 
detergents in membrane protein preparations for enhanced MS-based proteomic analysis,38,39 not 
to enrich low-abundance proteins based on their size. Compared to the in-solution digestion, the 
in-gel digestion also increases the digestion efficiency for membrane proteins [40,41]; this is 
possibly attributed to the decreased protein aggregation during digestion. By immobilizing 
hydrophobic membrane proteins in the gel matrix, aggregation of membrane proteins and large 
protein fragments produced at the initial stage of the protein digestion is likely minimized.   
2.3.2 SILAC CFTR as quantitation reference standard for absolute quantitation of PM 
CFTR 
The full-length CFTR quantitation reference standard was prepared through metabolic 
labeling using the SILAC method [31]. Lysates of BHK-wtCFTR cells cultured with media 
containing leucine-1,2-13C CFTR (seven doublings) were prepared by a buffer containing Triton 
X-100. The SILAC CFTR amount in the Triton X-100 extract was quantified against a highly-
purified, full-length native CFTR standard (this native CFTR could be used as the master reference 
standard for different laboratories) using the GEE method for sample preparation and LC-SID-
MRM MS for CFTR quantitation. Concentration of native CFTR was determined by amino acid 
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analysis to be 0.175 (±0.025) µg/µL. The quantity of SILAC CFTR was measured in triplicate 
using two signature peptides (CFTR01 and CFTR02). The protein concentration in the SILAC 
Triton X-100 extract was determined to be 4.72 (±0.07) ng/µL (Table 2.2). It should be noted that 
the SILAC CFTR reference standard was used as the Triton X-100 extracts directly for quantifying 
CFTR samples.   
 
Table 2.2: Preparation of SILAC CFTR quantitation reference standard. The area ratios between 
the native peptides and heavy isotope labeled peptides were used to calculate the concentration of 
SILAC CFTR in cell lysate, which was labeled with leucine-1,2-13C. Highly-purified full-length 
CFTR (300 ng) was used to calibrate the absolute amount of SILAC CFTR. Sample volume was 
30 µL.i 
 
A quantitative analysis was performed to examine the difference in CFTR between using 
the SILAC CFTR protein standard and using a stable isotopic synthetic peptide L(Δ7)-CFTR01. 
HEK293F-wtCFTR cells which overexpress wtCFTR upon induction with doxycycline at different 
concentrations (0, 0.25, 0.50, 0.75 and 1.0 µg/mL) were used. Apical PM CFTR was prepared by 
the tandem enrichment workflow (Scheme 2.1). One additional quantitation reference, peptide 
L(Δ7)-CFTR01, was added to the peptide mixtures resulting from in-gel digestion. Furthermore, 
five different samples were derivatized with different acid anhydrates (acetic, propionic, butyric, 
valeric, or succinic anhydride), respectively; with this sample-specific coding procedure, all five 
                                                          
i Work and table by Bekim Bajrami.  McShane, A. J.; Bajrami, B.; Ramos, A. A.; Diego-Limpin, P. A.; Farrokhi, V.; 
Coutermarsh, B. A.; Stanton, B. A.; Jensen, T.; Riordan, J. R.; Wetmore, D.; Joseloff, E.; Yao, X. Targeted 
Proteomic Quantitation of the Absolute Expression and Turnover of Cystic Fibrosis Transmembrane Conductance 
Regulator in the Apical Plasma Membrane. J. Proteome Res. 2014, 13, 4676-4685. 
Sample 
# 
Area CFTR01 Area CFTR02 
Area Ratio 
CFTR01 
Area Ratio 
CFTR02 
SILAC 
CFTR 
Amount 
(ng) 
Native L(Δ4) Native L(Δ6) Native/L(Δ4) Native/L(Δ6) 
1 4457 2100 10080 4703 2.12 2.14 140.8 
2 8690 3980 18850 9263 2.18 2.03 142.9 
3 3890 1810 7879 3717 2.15 2.12 140.8 
Average 141.5 
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samples were quantified in a single experiment of LC-SID-uMRM MS experiment [34]. The 
signature peptide CFTR01 was monitored in this study (Table 2.3). Expression of native CFTR in 
these doxycycline-inducible HEK293F-wtCFTR cells was determined according to both L(Δ4)-
CFTR01 and L(Δ7)-CFTR01. While both data sets observed the increased expression of CFTR, 
with the increase in the doxycycline concentration, CFTR amounts measured according to the 
peptide standard L(Δ7)-CFTR01—added after in-gel-digestion of CFTR—were only 14 to 17% 
of the corresponding measurements based on L(Δ4)-CFTR01, produced via in-gel digestion of 
SILAC CFTR (Table 2.3). This study shows that for absolute quantitation of membrane proteins 
like CFTR, it is essential to use protein standards to obtain better quantitation accuracy. 
The use of an isotopic protein reference allows for advantageous addition of an internal 
standard at an early step of sample preparation. For the PM CFTR quantitation, SILAC CFTR was 
added as the reference in the surface biotinylation fraction of membrane proteins before further 
sample preparations. In comparison, conventional LC-SID-MRM MS uses isotopic reference 
peptides [25-28,42].   For absolute quantitation of membrane proteins, peptide references are not 
acceptable. Membrane proteins are hard to digest; in a typical experiment the yield of signature 
peptide CFTR01 is only 14-17% and this yield varies from one sample preparation to another 
(Table 2.3). Furthermore, CFTR is prone to aggregation and degradation during sample 
preparation; for instance, preparation of CFTR for SDS-PAGE is performed at 30°C instead of 
boiling temperature. Addition of SILAC CFTR before GEE and protein digestion largely 
minimized variations in sample preparation and afforded the absolute quantitation of CFTR in 
CFBE cells. 
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Doxycycline 
(µg/mL) 
Relative Area CFTR01 Area Ratio Native CFTR 
Absolute 
Amount 
(ng)c 
CFTR 
Digestion 
Efficiency 
(%)d 
Native L(Δ4)a L(Δ7)b Native/L(Δ4) 
0 0 3802 16350 0 0 - 
0.25 3654 4229 15640 0.86 130 15 
0.75 4405 2110 7337 2.09 313 16 
1.00 3279 1103 3723 2.97 446 17 
1.25 29880 7560 30190 3.95 593 14 
 
Table 2.3: Absolute amounts of PM CFTR for HEK293F-wtCFTR cells. Area ratios 
(Native/SILAC) were used to calculate expressed native CFTR. a: 150 ng of SILAC CFTR was 
added to each sample; b: 500 fmol of L(Δ7)-CFTR01 was added; c: amount of PM CFTR for each 
10 cm plate; d: Relative areas for L(Δ4) and L(Δ7) peptides, together with the known amounts of 
SILAC CFTR and L(Δ7)-CFTR01, gave measurements for the digestion efficiency for CFTR. 
These numbers should represent the lower limits for the digestion efficiency, because sample loss 
during GEE and peptide preparation could also be attributed to the calculated efficiency.i 
 
2.3.3 Absolute quantitation of apical PM expression of CFTR in CFBE 41o- cells 
The CFBE cell line is a common model for CF research and drug development. We 
performed absolute quantitation of apical PM CFTR in CFBE 41o- cells grown on plates and 
snapwell filters via LC-MRM MS of signature peptides. Three signature peptides, CFTR01, 
CFTR02, and CFTR04 were monitored by LC-SID-MRM MS (Figure 2.3), but only CFTR01 and 
CFTR02 peptides were consistently able to be quantified for measuring their precursor CFTR 
protein in the PM, together with CFTR in the cytoplasm (i.e., CFTR in the Triton X-100 extract 
after removing PM CFTR). Quantitation results based on CFTR01 and CFTR02 were comparable 
(Table 2.2). Each sample was repeated with at least three different biological preparations. Results 
are summarized in Table 2.4. As expected, surface expression of CFTR in CFBE cells (14.1% of 
CFTR in the whole cell lysate) grown in snapwell filters is higher than that of CFBE cells grown 
in flasks (10.1%). CFBE cells grown on snapwell filters mimic airway epithelial cells with the air-
                                                          
i Work and table by Bekim Bajrami. McShane, A. J.; Bajrami, B.; Ramos, A. A.; Diego-Limpin, P. A.; Farrokhi, V.; 
Coutermarsh, B. A.; Stanton, B. A.; Jensen, T.; Riordan, J. R.; Wetmore, D.; Joseloff, E.; Yao, X. Targeted 
Proteomic Quantitation of the Absolute Expression and Turnover of Cystic Fibrosis Transmembrane Conductance 
Regulator in the Apical Plasma Membrane. J. Proteome Res. 2014, 13, 4676-4685. 
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liquid interface creating a polarized cell environment, increasing the PM expression of CFTR. The 
absolute quantitation method reported in this work will also enable accurate measurements of 
CFTR in primary cells. Absolute quantitation of PM CFTR will set the basis for the comparison 
of results and thus, greatly amplify the overall outcome of CF research and therapy. In reference, 
high reproducibility for LC-SID-MRM MS quantitation of protein targets in complex matrices has 
recently been shown for sample-to-sample, day-to-day, analyst-to-analyst, and lab-to-lab 
comparisons [26].  
 
Figure 2.3: LC-SID-MRM MS chromatograms of signature peptides for quantifying CFTR in 
the apical PM of CFBE cells grown on filters. Peptide denotations in Table 2.1.i 
 
 
 
 
 
 
 
 
                                                          
i Work and figure by Bekim Bajrami. McShane, A. J.; Bajrami, B.; Ramos, A. A.; Diego-Limpin, P. A.; Farrokhi, 
V.; Coutermarsh, B. A.; Stanton, B. A.; Jensen, T.; Riordan, J. R.; Wetmore, D.; Joseloff, E.; Yao, X. Targeted 
Proteomic Quantitation of the Absolute Expression and Turnover of Cystic Fibrosis Transmembrane Conductance 
Regulator in the Apical Plasma Membrane. J. Proteome Res. 2014, 13, 4676-4685. 
L(Δ4)-CFTR01
Endogenous CFTR01
Endogenous CFTR04
Endogenous CFTR02
L(Δ6)-CFTR02
L(Δ2)-CFTR04
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Sample CFTR Amount (ng/million cells) PM Expression (%) 
Plate, Biotinylated 2.90 ± 0.03 
10.3 ± 0.4 
Plate, Flow-through 25.0 ± 0.8 
Filter, Biotinylated 6.75 ± 0.18 
14.1 ± 2.0 
Filter, Flow-through 41.2 ± 4.7 
 
Table 2.4: Absolute quantitation and surface expression of CFTR protein in CFBE 41o- cells.i  
2.3.4 Turnover of CFTR in the apical PM 
We designed and performed the first quantitative analysis of CFTR turnover in the PM 
using stable isotopes. BHK-wtCFTR cells were originally cultured in native culture media. At time 
zero, culture media were switched to SILAC media containing stable isotope labeled lysine and 
arginine or leucine; thus, native CFTR in the PM started to decrease with time, and SILAC CFTR 
labeled with the stable isotopes started to appear and increase. At different time intervals, cells 
were harvested, and the protein fraction containing PM CFTR was processed according to the 
tandem enrichment workflow (Scheme 2.1). Native CFTR in the PM was quantified against the 
newly-synthesized isotopic CFTR by LC-SID-MRM MS of signature peptides. The time-course 
for the newly produced CFTR was followed for up to 60 or 84 hrs, through two experiments. The 
average area ratio of the signature peptides from the newly-incorporated CFTR versus the native 
CFTR (isotopic/native) was normalized to the maximum, and then the percentage of remaining 
native CFTR (denoted as R in Figure 2.4) was calculated.  The natural logarithm of R (for data 
points up to 48 h; incorporation of isotope labels were saturated beyond 48 h) was plotted against 
time and fitted according to 1st-order kinetics [11,43] with an adjusted R2 of 0.9496. The half-life 
(t1/2) of native CFTR in the PM was calculated to be 29.0±2.5 h.  
                                                          
i Work and table by Bekim Bajrami. McShane, A. J.; Bajrami, B.; Ramos, A. A.; Diego-Limpin, P. A.; Farrokhi, V.; 
Coutermarsh, B. A.; Stanton, B. A.; Jensen, T.; Riordan, J. R.; Wetmore, D.; Joseloff, E.; Yao, X. Targeted 
Proteomic Quantitation of the Absolute Expression and Turnover of Cystic Fibrosis Transmembrane Conductance 
Regulator in the Apical Plasma Membrane. J. Proteome Res. 2014, 13, 4676-4685. 
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Rescuing CFTR mutant proteins for expression in the apical PM is only the first step. The 
rescued mutants have to be stable in the membrane and perform the channel function for Cl- ions. 
It has been recently reported that the CF drug VX-809 can fully rescue the PM expression of 
F508del, but the lifespan of the rescued mutant falls short compared with that of wtCFTR [11]. 
Conventional western blot analysis of CFTR cannot be applied for turnover studies of PM CFTR. 
Although metabolic pulse-chase of radioisotopes provides a useful tool for this analysis [11], a 
more convenient method for accurate measurements of the protein turnover in the PM can be 
greatly beneficial to CF research and drug development. The combination of metabolic stable 
isotope labeling and quantitative proteomics is an emerging alternative to radioisotope methods 
[44,45].  Under this experimental framework, coupling the tandem enrichment of CFTR with 
highly sensitive MRM MS has made it possible to measure CFTR turnover (t1/2 = 29.0±2.5 hrs) in 
the PM of BHK-wtCFTR cells. In comparison, a shorter half-life (t1/2 ~14 hrs) was recently 
reported for CFTR in the whole cell lysate of the same cell line [11]. These results are in agreement 
with the observation that PM proteins degrade more slowly than do proteins that do not reach the 
membrane [43].  
Figure 2.4: Turnover of CFTR in the PM 
of BHK-wtCFTR cells. R represents 
normalized percentage degradation of 
native CFTR (see results and discussion). 
Blue and red data points were from two 
separate sets of experiments: isotopic 
leucine and isotopic arginine/lysine 
CFTR incorporation, respectively.  
Peptides CFTR01, 03, and 04 were 
monitored for the blue data points, and 
the individual transitions were used for 
the error calculations.  Peptides CFTR01-
04 were monitored for the red data points, 
and analytical triplicate measurements 
were used for error calculations (slope=-
0.0239±0.0021, adjusted R2=0.9496). 
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2.4 Conclusion 
Membrane receptors and transporters form the most important class of protein targets for 
understanding intercellular communication and developing new drugs. Recent advances in MS-
based quantitative proteomics, in combination with new sample preparation workflows, have made 
it possible to obtain unprecedented accuracy and precision in membrane protein measurements. 
Targeted quantitation of apical PM CFTR reported in this work exemplifies an important 
application of contemporary proteomics technologies and it will help significantly with 
understanding the disease mechanism of CF and developing future medicine for its treatment. 
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Chapter 3 
Ultrathroughput Multiple Reaction Monitoring Mass Spectrometry 
of Cystic Fibrosis Transmembrane Conductance Regulator in Cells 
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3.1 Introduction 
Multiple reaction monitoring (MRM) mass spectrometry (MS) has provided a versatile and 
relatively low-cost platform to promptly develop quantitative proteomics methods [1].  The 
analytical advantages of MRM-MS over traditional immunoassays, for protein quantitation, has 
been well documented [2].  These include the increased precision and accuracy of measurements, 
with dramatically lower coefficients of variation (CV) [3] and interlaboratory reproducibility [4].  
However, the sample throughput of immunoassays are incomparable.  Enzyme-linked 
immunosorbent assays (ELISA), are capable of 100s of samples being simultaneously quantified 
[5]. Towards increasing sample throughput for MRM-MS, several technologies have emerged that 
contain high-cost derivatizing reagents that depend on expensive isotopologues [6-12].  The 
integrated design of these reagents (sample-throughput and quantitation modules combined) 
renders statistically-significant numbers to be cost prohibitive for monitoring changes. When 
subtle changes are observed across proteomes, an increase in replicates is needed to give statistical 
significance to the data [13].  To achieve increased sample throughput (i.e. replicates), a modular 
design was adopted (sample-throughput and quantitation modules separated), dubbed 
ultrathroughput MRM (uMRM) [14].  This approach is adaptable for a handful of samples to 
potentially 100s.  To achieve sample throughput, inexpensive, non-isotopic reagents are used to 
derivatize proteolytic digests.  These reagents act as mass tags that allows each sample to be 
distinguishable in a mass spectrometer.  This gives uMRM an economic advantage over other 
integrated designs, and is not restricted to isotopologues.  Potentially infinite chemically diverse 
structures are available as derivatizing reagents. 
The second module, quantitation, is accomplished independent of the derivatizing reagents.  
This can be achieved by any number of techniques familiar to the proteomics field; such as, AQUA 
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peptides, 18O, metabolic labelling, etc... [15,16].  Since the sample-throughput and quantitation 
modules are separated, only one common reference standard is required.  The common reference 
standard in each sample would then go through the same derivatization as the sample.  This 
cheapens the analysis to a fraction of the price, transforming a triple quadrupole mass 
spectrometer’s intrinsic multiplexing capability to sample throughput.  Statistically significant 
numbers are now available through the increased throughput. 
This separated modular approach was applied to the quantitation of cystic fibrosis 
transmembrane conductance regulator (CFTR) protein.  Approximately 90% of patients with 
cystic fibrosis (CF) have a gene deletion of F508del that causes the subsequent premature 
degradation of CFTR, before reaching the plasma membrane [17].  We have previously described 
a targeted proteomic quantitation of CFTR, in the apical plasma membrane of mammalian cells 
[18].  The intrinsic difficulty of preparing large, hydrophobic membrane proteins was mitigated 
by using a dual enrichment strategy that involved cell-surface biotinylation and gel electrophoretic 
enrichment (GEE).  A whole protein internal standard (IS) was generated by the stable isotope 
labelling by amino acids in cell culture (SILAC) method [19].  
In the current work, the sample throughput will be increased with uMRM technology.  This 
will be demonstrated by 5 samples (varying ratios of IS to native) being quantified in triplicates.  
For traditional MRM MS analysis, this would require 15 MS experiments (5 samples x 3 replicates, 
~30 hours); however, using uMRM MS this would take 3 MS experiments (5-plex sample x 3 
replicates, ~6 hours).  This drastically decreases the instrument time needed for quantitation.  To 
achieve this throughput, non-isotopic amino acid reagents will be used to derivatize the free amines 
of the proteolytic digests.  The modular design is exploited by using the SILAC strategy for the 
quantitation module and the derivatizing reagents as the sample-throughput module.   
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To achieve near 100% coupling of the derivatizing reagents with the proteolytic peptides, 
a large molar excess of the reagents is required.  This renders a complicated sample, such as a cell 
lysate, to be additionally complicated with respect to precise, accurate MRM MS quantitation.  The 
measurement is further challenged by dilution.  An N-in-1 experiment requires sample pooling, 
thus an N-times dilution.  To enrich the analytes of interest and to simplify a difficult matrix, a 
biotin pull-down technique was utilized.  Similar to the ICAT® reagents [6], the thiols of cysteine-
containing peptides were alkylated with a biotin moiety.  The biotin moiety is easily added to thiols 
by replacing the typical alkylating reagents during trypsin digestion (e.g., iodoacetamide or 
iodoacetic acid) with iodoacetyl-LC-biotin.  After derivatization, the cysteinyl peptides are 
enriched by exploiting the well-known avidin/biotin affinity [20]. This affinity enrichment step 
not only removes the derivatizing reagents, but also simplifies the baseline matrix to only peptides 
containing cysteine.  Thus, improving the limit of quantitation. 
This N-in-1 experiment will allow 5 different samples with 3 replicates per sample to be 
quantified in 3 MS experiments.  Traditional MRM MS was performed requiring 15 MS 
experiments.  A comparison of precision will be made between the 2 methods.  This work will 
highlight the versatility and adaptability of the uMRM technology.  This will be the first time for 
uMRM MS, a whole protein IS is used as the quantitation module.  Furthermore, a biotin 
enrichment strategy is applied, to allow enrichment without a specific antibody, thus broader 
applications of this method are possible. 
3.2 Experimental 
3.2.1 Materials   
All reagents were purchased from Sigma-Aldrich (St. Louis, MO) or Fisher Scientific (Fair 
Lawn, NJ) unless otherwise specified below.  Direct-Q3 water system (Millipore, Billerica, MA) 
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was used to purify deionized water.  FMOC-Xxx-Osu amino acids were purchased from Chem-
Impex International (Wood Dale, IL).  Proteomics grade recombinant trypsin was purchased from 
Roche Applied Science (Indianapolis, IN).  The iodoacetyl-LC-biotin was purchased from 
ApexBio Technology (Houston, TX).  The cell line, baby hamster kidney overexpressing wild type 
CFTR (BHK-wtCFTR), was a gift from the Cystic Fibrosis Foundation.  Purified full-length CFTR 
samples were gifts from Dr. L. J. DeLucas (University of Alabama at Birmingham) and Dr. J. He 
(Accelagen, San Diego, CA). Purification of the later full-length CFTR sample was performed 
according to a procedure developed by Dr. J. R. Riordan at the University of North Carolina, 
Chapel Hill.  Amino acid analysis for the highly-purified, native CFTR was performed at the Keck 
Biotechnology Resource Laboratory at Yale University. DMEM, Ham’s F-12, DME/Low media 
deficient in L-arginine, L-leucine and L-lysine, and fetal bovine serum (FBS) were purchased from 
Thermo Scientific HyClone (Logan, UT). Dialyzed FBS and NeutrAvidin were purchased from 
Life Technologies (Thermo, Carlsbad, CA). 
3.2.2 Cell culture and lysate preparation   
BHK-wtCFTR cells were cultured in DMEM/Ham’s F-12 with 550 µM methotrexate, 5% 
FBS, and 1% of each of the following reagents: pen-strep, non-essential amino acids, and sodium 
pyruvate.  The lysis buffer (600 μL) containing 1% (v/v) Triton X-100, 150 mM NaCl, 20 mM 
Tris-HCl at pH 7.2, and 1% (v/v) protease inhibitors was used for the lysis of BHK-wtCFTR cells. 
3.2.3 SILAC internal standard preparation   
The heavy isotope labeled, full-length CFTR was obtained, by SILAC, from BHK-
wtCFTR cells cultured in DME/Low deficient in L-lysine, L-leucine, and L-arginine supplemented 
with 550 µM methotrexate, 0.4 mM L-arginine-13C6•HCl (Cambridge Isotopes, Andover, MA), 
0.8 mM L-lysine-13C6
15N2•2HCl (Cambridge Isotopes, Andover, MA), 0.8 mM L-leucine, and 5% 
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of dialyzed fetal bovine serum.  Cells grown in this heavy media were allowed at least 7 doublings 
prior to harvesting. 
3.2.4 Gel-based electrophoretic enrichment  
Gel electrophoresis was performed using a resolving gel consisting of 10% acrylamide and 
a stacking gel of 3% acrylamide. BioRad glass plates with 1.5 mm spacer plates and a 5-well comb 
were used.  CFTR samples were mixed with Laemmli sample buffer and incubated at 30oC for 20 
min. Gel electrophoresis was carried out at 120 V (constant voltage) for 35 min.  
3.2.5 Digestion   
           Gel pieces at the interface between the resolving and the stacking gels were excised. The 
gel pieces were washed (50 mM ammonium bicarbonate in H2O/acetonitrile), reduced (10 mM 
DTE), and alkylated (2 mM iodoacetyl-LC-biotin, see next section) before trypsinization (20 
ng/µL). The resulting digestion solution was dried via SpeedVac (Savant, Farmingdale, NY) and 
overnight lyophilization (Labconco, Kansas City, MO). 
3.2.6 Biotin alkylation of thiols   
The iodoacetyl-LC-biotin was first dissolved in pure DMSO, then diluted to a 2 mM 
concentration with 25 mM ammonium bicarbonate.  To determine the time necessary for alkylation 
of thiols, a time point study was accomplished.  Immediately after alkylation with iodoacetyl-LC-
biotin the gel pieces were washed, and 20 mM iodoacetamide (IAA) was added.  Transitions for 
iodoacetyl-LC-biotin and iodoacetamide alkylation were monitored.  Time points collected were 
0, 0.75, 1.5, 2.5, 5, 8, and 16 hr. 
3.2.7 Peptide derivatization   
Each sample was assigned a unique amino acid reagent for sample-specific derivatization. 
The activated FMOC-protected amino acid was dissolved in a solution of DIPEA/DMF at pH=8.  
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This solution was added to the dried digests, and incubated overnight at room temperature.  The 
reaction was then quenched with ice-cooled 20% formic acid and dried via SpeedVac and 
overnight lyophilization. 
3.2.8 Biotinylated peptide enrichment   
The dried, derivatized, and biotinylated digest was dissolved in 0.1 M borate buffer (boric 
acid adjusted to pH=7.4 with NaOH), added to 0.1 mg of NeutrAvidin, and incubated at RT for 60 
min.  The solution was then added to a 10 kDa MWCO Vivacon 500 (SartoriusStedim, Goettingen, 
Germany) membrane filter.  After washing with 0.1X PBS in 10% methanol, the derivatized, 
biotinylated peptides were eluted with 20% acetic acid in 30% methanol.  The product was then 
dried via SpeedVac and overnight lyophilization 
3.2.9 NanoLC-MRM MS   
The optimization and data analysis of this work was assisted by the Skyline software.  An 
Eksigent NanoLC-Ultra 2D+ (Redwood City, CA) was used at a flow rate of 250 nL/min with a 
self-packed Picofrit column (New Objective, Woburn, MA) filled with 15 cm of 2.7 µM diameter, 
160Ǻ pore Halo resin (MacMod, Chadds Ford, PA).  Solvent A was composed of 98.8% H2O, 
1.0% acetonitrile, and 0.2% formic acid (v/v) and solvent B’s composition was 98.8% acetonitrile, 
1.0% water, and 0.2% formic acid (v/v).  A typical gradient was 2%B at 0 min → 2%B at 20 min 
→ 47%B at 100 min → 80%B at 120 min with 10 min equilibration. Samples were loaded on the 
trap column at a flow rate of 3.5 μL/min at 1% solvent B for 10 min.  A triple quadrupole mass 
spectrometer was used, 4000 QTrap from ABSCIEX (Foster City, CA). 
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3.3 Results and discussion 
3.3.1 Enrichment of whole CFTR protein from cell lysates  
A modified CFTR enrichment strategy from a previous work was applied [18].  A gel was 
poured that localized CFTR protein to the interface between the stacking (3% acrylamide) and 
resolving (10% acrylamide) gels that lacked sodium dodecyl sulfate (SDS) (Figure 3.1a).  After 
mixing the sample buffer with the BHK-wtCFTR cell lysate, it was incubated at a gentle 
temperature of 30oC for 20 min to prevent CFTR degradation.  The total complexity reduction was 
calculated to be approximately 89% based on Ponceau S whole protein staining (Figure 3.1b).  
Since this method depends on the pull down of biotinylated peptides, endogenous biotinylated 
proteins were located (Figure 3.1c) to determine if they are co-localized with CFTR (Figure 3.1d).  
Ultimately, if a region of interest is biotin-rich, then more avidin should be used to ensure proper 
capture of all the biotinylated peptides.  For CFTR, the region above the orange marker (~148 
kDa) was excised for in-gel trypsin digestion.  This region has no strong bands for endogenously 
biotinylated proteins. 
Figure 3.1: Localization of CFTR and endogenously  
biotinylated proteins in BHK-wtCFTR triton X-100 cell 
lysate during modified SDS-PAGE: lysate incubation with 
Laemmli sample buffer containing 20% β-mercaptoethanol 
for 20 minutes at 30oC, 10% acrylamide resolving gel with 
no SDS, 3% acrylamide stacking gel with no SDS, 1 mm 
thickness gel with 10 wells (44 µL/well), and a 35 minute 
run time at 120V. (a) GEE [18] with the dotted line marking 
the interface between the stacking and resolving gel (b) 
Ponceau S staining of the total proteins on the PVDF 
membrane after transferring from gel: 90 minute transfer at 
30V.  After blocking, the PVDF membrane was cut, and the 
protein detection was performed in 2 separate dishes. (c) 
BCIP/NBT staining after 60 minute incubation with avidin 
conjugated with alkaline phosphatase (d) BCIP/NBT 
staining after 60 minute incubation with an anti-CFTR mAb-
596 (J. Riordan, UNC, NC) and a 30 minute incubation with 
a secondary antibody conjugated with alkaline phosphatase. 
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3.3.2 Biotinylation of cysteine-containing peptides during in-gel digestion and peptide 
selection for MRM MS   
The increase in sample complexity and sample dilution, from the respective derivatizing 
reagents and sample pooling, renders an enrichment strategy necessary.  A biotin handle is added 
to cysteinyl peptides by alkylating with iodoacetyl-LC-biotin (Figure 3.2).  This is similar the 
ICAT method, but the biotin alkylation does not possess isotopes and therefore is not responsible 
for quantitation [6].  From all possible biotinylated signature peptides, only those with one 
cysteine, 6-18 amino acids in length, and no cysteine at the N-terminus were chosen for MRM 
screening.  This criteria was chosen to ensure only one biotin moiety, allowable quadrupole m/z 
range, and no steric hindrance at the N-terminus for future derivatization, respectively.  From those 
8 peptides, 4 were able to be monitored by MRM MS (Table 3.1 and Figure 3.3). 
 
 
Figure 3.2: Structure of iodoacetyl-LC-biotin. 
Signature Cysteinyl CFTR Peptides 
LMGCDSFDQFSAER LDFVLVDGGCVLSHGHK EIFESCVCK 
QAFADCTVILCEHR ACQLEEDISK AYCWEEAMEK 
IFTTISFCIVLR IEAMLECQQFLVIEENK ISFCSQFSWIMPGTIK 
SIAIYLGIGLCLLFIVR QLMCLAR ECFFDDMESIPAVTTWNTYLR 
 
Table 3.1: Signature cysteinyl CFTR peptides after trypsin digestion.  The peptides in red were 
monitored in uMRM MS. 
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Figure 3.3: Chromatogram of signature cysteinyl peptides monitored by nanoLC-MRM MS 
without NeutrAvidin enrichment. 
 
3.3.3 Iodoacetyl-LC-biotin versus iodoacetamide alkylation of cysteines   
To determine the incubation period for full iodoacetyl-LC-biotin alkylation of cysteines, a 
time trial was performed.  After the iodoacetyl-LC-biotin alkylation, iodoacetamide was added.  
Once trypsinization was completed, transitions for iodoacetyl-LC biotin and iodoacetamide 
alkylation were monitored by MRM MS.  After 45 min, no iodoacetamide alkylation was seen.  
Digests from separately alkylated digests (IAA and iodoacetyl-LC-biotin) are comparable for both 
cysteinyl (ACQ, AYC, and LMG) and non-cysteinyl peptides (CFTR01 and CFTR02) (Figure 
3.4).   
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Figure 3.4: Thiol alkylation with iodoacetamide (a) and iodoacetyl-LC-biotin (b) before 
trypsinization.  ACQ, AYC, and LMG are cysteine-containing peptides of CFTR, where CFTR01 
and CFTR02 are not. 
 
3.3.4 Pull down of biotin-containing peptides to reduce sample complexity   
The biotin-containing peptides were pulled down with free NeutraAvidin (a deglycosylated 
avidin) protein.  This provided a scalable approach to economically enrich large amounts of 
biotinylated peptides, and also eliminate non-specific binding to the immobilization matric of 
solid-phase avidin reagents.  According to bicinchonimic acid (BCA) analysis, the protein 
concentration from the BHK-wtCFTR lysates are 2.05±0.03 mg/mL (NanoDrop 2000c, 
ThermoScientific, Wilmington, DE).  Only 10.5% of the proteins exist at the excised, interfacial 
band (Figure 3.1b).  Assuming all the protein at the interface is CFTR and digested at 100% 
efficiency, 40.9 µg of cysteine-containing peptides are present in the digest.  Therefore using 0.1 
mg of NeutrAvidin is over double what is required.  After incubating the avidin and biotinylated 
peptides together, they were placed on a 10 kDa molecular weight cut off filter and centrifuged.  
The non-biotinylated peptides were washed away with methanol/water washes.  The biotinylated 
peptides were separated from the NeutrAvidin with an acidic solution.  The filtrate was then dried 
and stored at -20oC until MRM MS analysis.  This simple filter-assisted method was quite effective 
as shown in Figure 3.5.  This enrichment step is essential because of the increase in sample 
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complexity caused by the derivatizing reagents.  A large excess of reagents is required to ensure a 
chemical conversion of the biotinylated, derivatized peptide.  Secondly, when pooling the samples 
for uMRM analysis, a dilution occurs that is overcome by this enrichment step.   
 
Figure 3.5: Enrichment of cysteinyl peptides with NeutrAvidin on a 10 kDa molecular weight cut 
off filter. (a) Filtrate after 30 min incubation of the CFTR digest with NeutrAvidin.  This step 
washes away the non-cysteinyl peptides (CFTR01 and CFTR02) with the cysteinyl peptides (ACQ, 
AYC, and LMG) bound to the NeutrAvidin.  No cysteinyl peptides were seen in this filtrate 
ensuring a proper amount of NeutrAvidin was utilized (b) Filtrate after 10 min incubation with 
20% acetic acid in a 30% methanol solution.  This step separates the cysteinyl peptides (ACQ, 
AYC, and LMG) from the NeutrAvidin.  Very little non-cysteinyl peptides are seen (only a weak 
CFTR02 signal).  This ensures that we are able to separate cysteinyl from non-cysteinyl peptides. 
 
3.3.5 Derivatization of biotinylated peptides   
To achieve the sample throughput module of uMRM, a derivatizing step is needed.  In this 
study, the derivatizing reagents were FMOC-Xxx-OSu amino acids.  The N-terminus alkylation 
prevents polymerization, when the coupling agents are added to the digests.  In the near future, 5 
different FMOC-Xxx-Osu amino acids will be used to derivatize 5 different BHK-wtCFTR 
digests.  This will be accomplished in biological triplicates. 
3.3.6 BHK-wtCFTR lysate preparation for CFTR quantitation   
Five different ratios of native BHK-wtCFTR and SILAC BHK-wtCFTR lysate were 
combined to compare traditional MRM MS to uMRM MS.  The ratios in Table 3.2 were made 
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from common stocks of the appropriate lysate.  Each ratio was quantified in triplicate via 
traditional MRM MS; i.e., gel-fractionated, digested, desalted, and nanoLC-MRM MS separately.  
A triplicate uMRM MS measurement will also be made; i.e. each sample gel-fractionated, 
digested, and derivatized separately, but then pooled before enrichment and nanoLC-MRM MS 
(Figure 3.6).  This will yield a 5 times reduction in analysis time, and enable analytical significant 
numbers more feasible. 
Ratio (Native/SILAC) Volume of BHK-wCFTR 
Lysate (uL) 
Volume of SILAC BHK-
wtCFTR Lysate (uL) 
0.33 150 450 
0.50 200 400 
1.0 300 300 
2.0 400 200 
3.0 450 150 
 
Table 3.2: Sample ratios of the native BHK-wtCFTR to the SILAC BHK-wtCFTR lysate.  The 
lysates were of common stock for both the traditional and uMRM MS experiments.  Triplicates of 
each sample were prepared for both experiments. 
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Figure 3.6: Five-plex uMRM MS strategy.  A sample-specific amino acid will be added to each 
sample to create the multiplexing module of the design.  Each sample will be analyzed in 
triplicates, and compared to traditional MRM MS. 
 
3.3.7 Traditional MRM MS of the mixed lysate solutions 
 The 5 ratios of native to SILAC BHK-wtCFTR lysates (0.33, 0.50, 1.0, 2.0, and 3.0) were 
gel fractionated, in-gel digested, and desalted in triplicate before nanoLC-MRM MS measurements 
were accomplished.  Peptides CFTR01 through CFTR04 were used for quantitation with 3 
transitions monitored from each individual peptide [18].  The peak area ratios of the native to 
SILAC CFTR were averaged and plotted in Figure 3.7.  The peak area ratios and the volume ratios 
of native to SILAC BHK-wtCFTR lysate correlated linearly with an adjusted R2 of 0.9984.  This 
represents that the experiment parameters are well within the limit of linearity.  Also the standard 
error is very minimal for each ratio demonstrating the precision of the CFTR quantitation method.  
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Figure 3.7: Relationship between the peak area ratios and the lysate solutions.  Five different 
lysate ratios of native and SILAC BHK-wtCFTR lysates were made: 0.33, 0.50, 1.0, 2.0, and 3.0 
(native/SILAC).  Biological triplicates of each ratio were then acquired from gel fractionation to 
nanoLC-MRM MS measurement. 
 
3.3.8 Future work 
 The completed traditional MRM MS experiments will serve as the basis of comparison to 
the uMRM MS analyses.  The 5 different lysate solutions, from a common stock with the MRM 
MS analyses, was gel fractionated and in-gel digested.  However, a biotin handle was added during 
the alkylation of the cysteine residues.  These were prepared in triplicate, and ready for the next 
step of the uMRM MS strategy, derivatization.  In the future, each ratio will be alkylated with a 
specific FMOC-Xxx-Osu.  The derivatized, biotinylated peptides will then be combined and pulled 
down with NeutrAvidin.  After elution and drying, the sample will be analyzed via nanoLC-uMRM 
MS.  A comparison will then be made between the MRM and uMRM MS. 
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3.7 Conclusion 
 By using non-isotopic, inexpensive derivatizing reagents affordable and immensely 
expandable sample throughput is possible for MRM MS.   With this uMRM methodology, a single 
common IS allows for concurrent quantitation of the same surrogate peptides in multiple samples 
via sample-specific derivatization.  The amount of multiplexing is controlled by the mass 
spectrometrist from a few samples to potentially hundreds.  The analysis of a statistically 
significant number of samples or proteomes with a large protein concentration (e.g. serum) are 
now more practical.  This technology has the potential to shift the paradigm of derivatization-based 
methods for improving sample throughput. 
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Chapter 4 
Peptide Dimethylation: Fragmentation Control via Distancing the 
Dimethylamino Group 
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4.1 Introduction 
The use of peptide derivatization is a staple of proteomic quantitation [1].  Derivatization-
based mass spectrometry (MS) quantitation is characterized by its sample-throughput capabilities 
allowing multiple samples to be analyzed simultaneously.  Different applications are dependent 
upon fragmentation control of the derivatized peptide.  In applications of isobaric mass tagging 
reagents [1,2], the derivatized peptides are isobaric, but after fragmentation produce differentiable 
reporter ions in tandem MS (MS/MS) spectra.  Peptide derivatization with these types of reagents 
are Type I active derivatizations (Scheme 4.1), classified by the strong signals directly observed 
from the fragmented derivatization group [3].  One significant pitfall of these reagents is the limited 
dynamic range, which is caused by all the derivatized peptides sharing common reporter ions; 
therefore, peptides with similar masses and elution time produce elevated background for the 
peptides in quantitation [4,5].  
Scheme 4.1: Categorization of peptidyl chemical derivatizations. 
Reductive methylation has been used as both mass-difference tagging for MS quantitation 
[6-8] and recently isobaric mass tagging for MS/MS quantitation [9-11].  Dimethylation is a 
relatively simple reaction only requiring a reducing agent and formaldehyde.  This reaction is 
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expeditious without any substantial formation of side products. When stable isotope labels are used 
in the reducing agent and/or formaldehyde, peptides can be introduced with a designed number of 
stable isotope labels for MS-based quantitative measurements. This method has been broadly 
applicable due to its easy implementation [12].  
The molecular basis for MS/MS quantitation of peptides with direct dimethylation is the 
facile collisional cleavage of the first N-terminal amino acid residues.  Strong signals for 
derivatized a1 ions (stable quaternary amine ions) are characteristic in MS/MS spectra of the 
derivatized peptides [13-15]. Dimethylation of peptides is considered a Type II active 
derivatization, where the derivatizing group promotes the cleavage of the first amide bond of 
peptides (Scheme 4.1). Collisional fragmentation of directly dimethylated peptides has been 
studied in detail [14,15]. When the methyl groups carry differential stable isotope labels, the 
derivatized peptides can, in principle, be quantified based on the correspondingly labeled a1 ions.  
This quantitation using MS/MS measurement could be advantageous. These a1 ions are peptide-
specific and thus lessen the interference from co-eluting peptides experienced for peptides 
derivatized with isobaric mass tagging reagents. In order to observe such interference, derivatized 
peptides would need to have similar elution times and masses as well as the same first N-terminal 
amino acid residue; a rare occurrence.  However, authentic quadrupole sampling of dimethylated 
peptide ions with different numbers of isotope labels as precursors can be problematic. Efforts 
have been made to develop an isobaric mass tagging capability using peptide dimethylation. One 
method derivatizes peptides at both N- and C-termini, but with complementary numbers of stable 
isotope labels. In this method, triplex isobaric peptide termini labeling with dimethylation, peptide 
precursors are isobaric and fragment ions carry differentiable stable isotope labels and thus the ion 
intensity of the fragments can be used for quantitation [9].   
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In line with recent advancements in the utilization of ultra-high resolving MS for 
proteomics, differences in mass defects of carbon, hydrogen, oxygen, and nitrogen isotopes have 
been exploited [10, 11, 16-19]. The scope of isobaric mass tagging is thus being expanded, opening 
exciting new opportunities in proteome quantitation. In principle, all of the currently practiced, 
derivatization-based quantitative proteomic methods can be adapted to better utilize contemporary 
mass spectrometers. Two recent reports use peptide dimethylation. Peptides in comparison carry 
derivatizing groups with different isotopologue labels, i.e., two atoms of 13C versus 2H. Therefore, 
during the low-resolution selection of precursor ions, the differentially-labeled peptides are co-
selected authentically. However, when MS/MS are recorded with ultra-high resolving power, 
fragment ions can be baseline-separated for quantitation. Both works use Lys-C for protein 
digestion so that each resulting peptide carries two derivatizing groups. It is interesting to note that 
there are more derivatized y ions than b ions available to be used for quantitation [10,11]; in other 
words the ε-dimethylamino group on the lysine side chain at the peptide C-terminus is more stable 
than the α-dimethylamino group at the N-terminus. 
Multiple reaction monitoring (MRM) MS is at the forefront of targeted, quantitative MS 
due to its high selectivity, sensitivity, and method robustness [20].  Stable isotope labeled 
references are commonly used to assemble methods for stable isotope dilution (SID) MRM MS.  
The generation of quantitation reference peptides can be achieved by derivatizing peptides with 
stable isotope labeled chemicals for mass-difference tagging [21,22].  Although the quantitation 
utility of the derivatized reference peptides can be comparable to those produced by metabolic 
labeling techniques [23], these reagents have yet to be broadly adopted. The limited adoption of 
the commercial reagents for MRM MS exemplifies a common problem for using active 
derivatizations of peptides for MRM-based MS quantitation: the derivatizing groups are not 
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efficiently held as intact mass tags for the precursor ions of the derivatized peptides or for their 
fragments.  
MRM-based methods require the detection of strong signals for both precursor ions and 
fragment ions to obtain low quantitation limits.  Furthermore, multiple distinguishable fragment 
ions are preferred to secure the method’s specificity.  If the derivatizing group is cleaved from the 
fragment ions, these fragments are no longer distinguishable among peptides with differential 
derivatizations.  Therefore, MRM-based quantitation can benefit from passive derivatization of 
peptides (Scheme 4.1) [3]: during MRM analysis, derivatized peptides preserve the derivatizing 
groups on the intact peptide precursor ions in the ionization region of the instrument and keep 
these derivatizing groups on multiple fragment ions during fragmentation of the derivatized 
peptides in the collision cell.  We hypothesize that if the dimethylamino group on derivatized 
peptides is disengaged from the adjacent amide bond, then a passive derivatization will be achieved 
for MRM-based peptide analysis.  This derivatization will keep the increased gas-phase basicity 
of dimethylamino peptides, from the tertiary amine of the dimethylamino group, and accordingly 
the enhanced MS signals [24], but not activate particular peptide bonds in a biased manner.  Herein, 
we present a systematic study of how diversely a dimethylamino group participates in collisional 
fragmentation of peptides with the increased distance from the first N-terminal amino acid residue. 
In addition, the change of role for the dimethylamino group from an active participant in 
fragmentation to a passive mass tagging one is reported. 
4.2 Experimental 
4.2.1 Chemicals  
2-aminoacetic acid (>99%), 3-aminopropanoic acid (99%), 4-aminobutanoic acid (>99%), 
5-aminopentanoic acid (>97%), 6-aminohexanoic acid (>99%), methanol (>99.9%), diethyl ether 
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(>99%), glacial acetic acid (>99.7%), N,N-diisopropylethylamine (99.5%, DIEA), N-
hydroxysuccinimide (98%, NHS), dimethyl sulfoxide (>99.7%, DMSO), anhydrous N,N-
dimethylformamide (>99.8%, DMF), 4-(4,6-dimethoxy-1, 3, 5-triazin-2-yl)-4-
methylmorpholinium chloride (≥96.0%, DMTMM), N- (3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (≥98.0%, EDC), and anhydrous dichloromethane (>99.5%, 
DCM) were purchased from Sigma-Aldrich (St. Louis, MO).  Formic acid (88% and 99.5%), 
trifluoroacetic acid (97%, TFA), acetonitrile (99.9%, ACN), and formaldehyde (37%) were 
purchased from Fisher (Hanover Park, IL). Concentrated hydrogen chloride acid (36.5% - 38%) 
was purchased from J.T. Baker (Center Valley, PA).  N, N'-diisopropylcarbodiimide (99%, DIC) 
was purchased from Alfa Aesar (Ward Hill, MA).  The ultrapure water was obtained from a Direct-
Q 3 UV water purification system (EMD Millipore, Billerica, MA). The peptides 
LSLVPDSEQGEAILPR (95%), LSEPAELTDAVK (99%), YGGFLR (98%), and SVILLGR 
(99%) were purchased from Peptide 2.0 (Chantilly, VA).  The peptide NSILTETLHR (95%) was 
purchased from Anaspec (Fremont, CA).  The isotopic peptide SVIL[L-13C6
15N]GR (99%) was 
purchased from Thermo Fisher (Rockford, IL). 
4.2.2 Dimethylamino acid synthesis 
Each amino acid (8 mmol) was dissolved in formic acid (5 mL, 88%) and formaldehyde (1 
mL). The synthesis of 3-(dimethylamino)-propanoic acid (denoted as dim-3), 4-(dimethylamino)-
butanoic acid (denoted as dim-4), 5-(dimethylamino)-pentanoic acid (denoted as dim-5), and 6-
(dimethylamino)-hexanoic acid (denoted as dim-6) was carried out in a microwave reactor (CEM 
Discover-S, Matthews, NC), with the following conditions: 100 W, 110 °C, 20 to 120 min.  2-
(Dimethylamino)-acetic acid (denoted as dim-2) was conventionally refluxed at 100 °C for 1 hour.  
Concentrated HCl (1 mL) was added after heating.  The solvent was dried in vacuo.  After drying, 
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a white precipitate was obtained and washed with glacial acetic acid (5 mL) three times.  The 
dimethylamino acid was then recrystallized with methanol and diethyl ether.  After purification, 
the reagents were characterized with nuclear magnetic resonance (NMR) spectroscopy (Avance 
III 400 MHz, Bruker, Billerica, MA) and high-resolution MS (AccuTOF™ DART, JEOL, 
Peabody, MA, USA).  Detailed syntheses and characterizations can be found in Appendix-1 Text 
A1.1-A1.5. 
4.2.3 Peptide derivatization 
The dimethylamino acid (1.0 equivalent), NHS (1.2 equivalents), and DIC (1.0 equivalent) 
were first dissolved in DMSO, and then diluted with anhydrous DCM.  The solution was incubated 
overnight at room temperature. A solution containing five peptides, NSILTETLHR, 
LSLVPDSEQGEAILPR, LSEPAELTDAVK, YGGFLR, and SVILLGR dissolved in 10% 
DIEA/DMF, was added to the activated dimethylamino acid.  The solution was incubated 
overnight at room temperature. The coupling was then quenched with 20% formic acid/H2O on 
ice. The solution was first dried with a speed-vac (Savant SC100, Thermo Fisher) then lyophilized 
(Labconco FreeZone Plus, Kansas City, MO, USA).  After drying, the sample was desalted via an 
empty spin column (Thermo Fisher) packed with hydrophilic-lipophilic-balanced (HLB, Oasis®, 
Waters, Milford, MA, USA) reversed-phase sorbent.  The sample was then dried and reconstituted 
with FA/H2O for liquid chromatography (LC)-MS analysis (Shimadzu HPLC pumps/controller, 
Kyoto, KYT, Japan and HTC PAL autosampler, Carrboro, NC). 
4.2.4 LC-MS and LC-MS/MS studies 
A 10 cm, 1.0 mm I.D. Hypersil Gold HPLC column (Thermo Fisher Scientific, Inc., USA) 
with 175 Å, 3 μm C18resin was used.  Solvent A was composed of 98.8% H2O, 1.0% ACN, and 
0.2% FA and solvent B was 98.8% ACN, 1.0% H2O, and 0.2% FA.  The LC gradient was 5% to 
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35% solvent B for 45 minutes.  The column temperature was 60 °C.  The hybrid mass spectrometer 
used was a QSTAR® Elite (AB Sciex, Framingham, MA).  Positive electrospray ionization (ESI) 
was used, with parameters of 5.5 kV for the spray voltage and source temperature of 300 °C.  The 
initial collision energies (CE) for the doubly- and triply-charged peptides were obtained from 
Equations 4.1 and 4.2, respectively [25].   
Equation 4.1: CE = (0.057 × m/z) – 4.265 
Equation 4.2: CE = (0.031 × m/z) + 7.082 
These equations were empirically adjusted for the non-derivatized peptides (Appendix-1 Table 
A1.1), and for dim-2-peptides (Appendix-1 Table A1.2).  The new equations from the dim-2-
peptides were applied to the dim-3- through dim-6-peptides. 
4.2.5 Energy resolved (ER)-MS studies 
An AB SCIEX 4000 QTRAP® (AB SCIEX, Framingham, MA) triple quadrupole mass 
spectrometer with direct syringe infusion of the sample solutions was used for the ER-MS studies.  
The ESI was in positive mode with parameters of 5.5 kV for the ion spray and a source temperature 
of 200 °C.  Each peptide (500 fmol/µL) was individually infused with a flow rate at 5 µL/min.  
The DP was optimized before the collision studies were started.  The CE was ramped from 5 to 40 
V in 0.5 V/s increments.  The resolution was set to unit for Q1 and high for Q3.  The dwell time 
was 200 msec.  Three replicates were taken for each peptide measured (non-derivatized YGGFLR 
through dim-6-YGGFLR). 
4.3 Results and discussion  
4.3.1 Microwave-assisted synthesis of dimethylamino acids  
The established Eschweiler-Clarke reaction [26,27] was used to dimethylate the primary 
amines of five amino acids: 2-aminoacetic acid, 3-aminopropanoic acid, 4-aminobutanoic acid, 5-
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aminopentanoic acid, and 6-aminohexanoic acid. They have increasing numbers of methylene 
groups, one through five (dim-2 through dim-6, respectively), distancing the amino group from 
the carboxylic acid. Full conversion of 3-aminopropanoic acid to dim-3 required 8 hours of 
conventional refluxing. Other amino acids were even less reactive towards amine dimethylation.  
In an attempt to expedite the dimethylation of 3-aminopropanoic acid to 6-aminohexanoic acid, 
microwave irradiation was utilized.  All of the initial five substrates were converted to the 
corresponding products within 20 to 120 minutes of irradiation (Appendix-1 Text A1.1-A1.5). 
4.3.2 Preparation of dimethylamino peptides 
Five synthetic peptides were used as models to investigate collisional fragmentation 
mechanisms of dimethylated peptides: NSILTETLHR, LSLVPDSEQGEAILPR, 
LSEPAELTDAVK, YGGFLR, and SVILLGR.  They possess a wide variety of properties 
(Appendix-1 Table A1.3).  Peptide LSEPAELTDAVK was chosen as a model peptide for lysine-
containing peptides, which have two primary amines. Tandem mass spectra for these non-
derivatized peptides are shown in Appendix-1 Figures A1.1a-A1.1f. 
Peptidyl amino groups on the model peptides were derivatized with dimethylamino acids 
whose carboxylic groups were activated in situ (Scheme 4.2). The activation of carboxylic groups 
was mediated by DIC and NHS. Solvent played a dominating role in this peptide derivatization. 
The dimethylamino acids were soluble in aqueous solution. However, derivatization of the 
peptides using water-soluble mediation reagents, including EDC/NHS and DMTMM, resulted in 
low and varying yields for the derivatization products.  A mixed solvent of DMSO and DCM 
served well for activating the dimethylamino acids using DIC/NHS.  This solvent system was 
miscible with the mixture of DIEA and DMF, which was used as the solvent for preparing peptide 
solutions for derivatization. 
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Scheme 4.2: General reaction for derivatizing peptidyl amines with dimethylated amino acids. 
4.3.3 MS signal enhancement of dimethylamino peptides 
The percentage of chemical conversion (PCC) and signal yield for mass spectrometry 
(SYMS) were quantitatively measured for peptides dim-2-SVILLGR through dim-6-SVILLGR. 
After quenching the derivatization reaction, an equal amount of isotopically labeled SVIL[L-
13C6
15N]GR was added as the quantitation reference, although GSVIL[L-13C6
15N]GR would be a 
closer reference.  The MS signal for the residual unreacted SVILLGR, compared to that for the 
isotopic quantitation reference, allowed for calculation of the PCC value for each derivatization. 
The average PCC for all five derivatizations of SVILLGR was 85% (Appendix-1 Equation A1.1).  
Further optimization of derivatization reactions was not performed in this work, because these 
reactions were used to generate sufficient amounts of dimethylated peptides for mechanistic 
investigations not to be directly applied for proteome quantitation. The SYMS value for a 
derivatization was calculated based on the MS signal of the derivatized peptide, e.g., dim-2-
SVILLGR, and that of the isotopic quantitation reference. The average SYMS for all five 
derivatized peptides was 170% (Appendix-1 Equation A1.2).  This average SYMS was further 
corrected for the derivatization completeness (or average PCC), giving an adjusted SYMS of 200% 
(Appendix-1 Equation A1.3), for the addition of dimethylamino acids to the N-terminus of 
SVILLGR.   
The enhanced MS signal for the derivatized peptides can be attributed to the increased gas-
phase basicity, compared to the underivatized SVILLGR. These derivatizations convert a primary 
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N-terminal amino group to a tertiary amine which is more basic and results in more favorable 
protonation in the gas phase. Signal enhancement of 130% to 240% was also reported for peptides 
with dimethylated lysine side chains, compared to their non-dimethylated counterparts [24]. The 
increased basicity of peptides carrying the dimethylamino group is likely also attributing to the 
charge-state shift from a mixture of singly- and doubly-charged ions for SVILLGR and YGGFLR 
to the mostly doubly charged for their derivatized counterparts, and predominantly doubly-charged 
LSLVPDSEQGEAILPR to a doubly and triply-charged mixture (Appendix-1 Figure A1.7a-
A1.7c).  The coalescence to doubly-charged SVILLGR from the singly- and doubly-charged 
mixture could also attribute to the increase in SYMS.  
4.3.4 Fragmentation dependence of dimethylamino peptides on alkyl chain length 
Tandem MS was performed on a QqTOF mass spectrometer for all of the derivatized 
peptides.  The derivatized YGGFLR peptides are used as the exemplary peptides for discussion, 
with all others in the SI (Appendix-1 Figures A1.1-A1.6).  The CE was empirically adjusted using 
Equations 4.1 and 4.2 to ensure proper fragment ion production.  The dim-2-peptides were used 
for the empirical adjustment, and the CE was increased by 1.1 to 1.5 times, compared to the 
suggested values from the equations (Appendix-1 Table A1.3).  The CE was adjusted until an 
approximate <10% precursor ion was observed after collision-induced dissociation (CID).  
Equations 4.1 and 4.2 were then corrected accordingly for other dimethylamino peptides.  As 
shown in Scheme 4.3, fragment ions are denoted with typical nomenclature except for the 
following: (1) b and a ions carrying the derivatizing group are denoted as *b and *a respectively, 
(2) b and a ions carrying a cyclization product of the derivatizing group are denoted as cb and ca 
respectively, (3) ions from the bond cleavage between the α and β carbon from the dimethylamino 
group is denoted as f1, (4) b and a ions carrying an acetyl group  (the complementary products 
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from the α-β cleavage) are denoted as ab and aa, respectively, and (5) the ions from the amide bond 
cleavage between the derivatizing group and the original N-terminus of the peptide is denoted as 
f2,  and the corresponding production of the singly-charged ion as the original peptide is denoted 
as oM.  A general trend of the increased coverage of b and derivatized b ions was observed for the 
derivatized peptides compared to their underivatized counterparts (Appendix-1 Figures A1.1-
A1.6) [6]. 
 
Scheme 4.3: Nomenclature of fragment ions as represented by dim-3-YGGFLR. 
Dim-2 derivatization results in peptides with the same chemical structure as peptides with 
direct reductive dimethylation; collisional fragmentation mechanism for the directly methylated 
peptides has been studied in detail (Scheme 4.4a) [14,15]. For instance, dim-2-YGGFLR (MS/MS 
spectrum shown in Figure 4.1) is the same as dimethylated GYGGFLR.  Dimethylated peptides 
are known to produce enhanced signals for *a1 ions [13-15].  In the nomenclature system used in 
this paper, the f1 ion was observed for dim-2-YGGFLR (or *a1 for dimethylated GYGGFLR) at 
m/z 58.06 (Figure 4.1; Scheme 4.4). Generation of f2 ions (or *b1 for dimethylated GYGGFLR) 
at m/z 86.20 can be accounted for by the oxozolium mechanism [28] or the aziridin-2-one pathway 
(Scheme 4.4b) which further produces the f1 ion [29].  Generation of f2 ions suggests the favorable 
protonation of the dimethylamino group and a facile intramolecular proton transfer to activate the 
adjacent amide group in the derivatized peptides (Scheme 4.4b). In other words, there is an active 
participation of the derivatizing group in the peptide fragmentation.  
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Figure 4.1: MS/MS spectrum of dim-2-YGGFLR. 
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Scheme 4.4: Mechanism of f1 production from dim-2 derivatized peptides. 
Dim-3 derivatization extends the distance by one additional methylene group between the 
dimethylamino group and the first amide group on the derivatized peptides, which is formed upon 
the attachment of a dimethylamino propionic acid.  Two intense ions at m/z 58.06 (f1) and m/z 
754.36 [MH-f1]
+ were observed for dim-3-YGGFLR, together with significant signals for acetyl b 
ions (ab1, 
ab2,
 ab3, and
 ab4), shown in Figure 4.2. The sum of m/z 58.06 and m/z 754.36 made up the 
mass balance for dim-3-YGGFLR, suggesting the existence of a labile bond. Generation of these 
2 ions can be readily explained by the McLafferty-type rearrangement (Scheme 4.5) [30]. It should 
be noted that although the ion structure for f1 ions for dim-2-peptides and dim-3-peptides are the 
same, mechanisms for the ion generation are different (Schemes 4.4 and 4.5). In general, the f1 ion 
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was observed for all dim-3 peptides (Figure 4.2 and Appendix-1 Figure A1.3). On the other hand, 
not all of the corresponding [MH-f1]
+ ions were observed (Appendix-1 Figure A1.3), which could 
be due to further breakage of the primary [MH-f1]
+ fragment ions under experimental conditions. 
According to the categorization of peptide derivatization shown in Scheme 4.1, the dim-3 reaction 
would be classified as a Type I active derivatization, where there is preferential cleavage within 
the derivatizing group. 
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Figure 4.2: MS/MS spectrum of dim-3-YGGFLR. 
A common, neutral loss of dimethylamine was observed for doubly-charged ions of dim-
4-, dim-5-, and dim-6-YGGFLR, producing corresponding doubly-charged fragments (Scheme 
4.6). Dim-4 derivatization produced a very strong fragment ion at m/z 390.75 (cyc2+, Figure 4.3). 
Dim-5-YGGFLR gave a doubly-charged ion at m/z 397.73 (cyc2+) as the most intense fragment 
(Figure 4.4). These two ions are proposed as YGGFLR carrying an imido lactone at the N-
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terminus (Scheme 4.6). A complement of b and a ions carrying the imido lactone, i.e., cb and ca 
ions, were observed for dim-4- and dim-5-YGGFLR. Formation of these ions can be explained by 
nucleophilic substitution of the amide oxygen to the α-methylene carbon of the dimethylamino 
group (Scheme 4.6). Similar mechanisms were reported in a fragmentation study of lysylglycine 
[31] and used for explaining the charge mobilization of peptides derivatized with a quaternary 
amine [32] and loss of dimethylamine from Nε-dimethyllysine [33]. Dim-6-YGGFLR produced a 
similar cyclization product at m/z 404.72 (cyc2+, Figure 4.5), but at a much reduced intensity and 
without observable complementary ca and cb ions. The intensity differences could be related to the 
stability of imido lactone rings. 
Doubly-charged dim-6-YGGFLR, compared to dim-4- and dim-5-YGGFLR, produced full 
series of *a and *b ions carrying the derivatization group, together with y ions (Figures 4.3-4.5). 
This suggests that in the dim-6-peptide the preferential cleavage via the mechanism in Scheme 4.5 
becomes much less competitive. In other words, the dim-6 derivatization is passive (Scheme 4.1). 
Similar results were also observed for other dim-6 derivatized peptides (Appendix-1 Figure 
A1.6). It is also interesting to note that the intensity for the residual doubly-charged precursor was 
high (Figure 4.5), using the collision energy obtained from the same calculation as those for other 
derivatized peptides (Appendix-1 Table A1.2), dim-2-YGGFLR through dim-5-YGGFLR.  
Double derivatization of LSEPAELTDAVK was obtained at both the N-terminus and the 
lysine side chain. For example, dim-4-LSEPAELTDAVK (Appendix-1 Figure A1.4d) produced 
fragments that corresponded to the cyclization occurring at both sites.  The first cyclization product 
(m/z 727.45) was 80% relative intensity and the second (m/z 704.90) was 30% relative intensity.  
In comparison, one cyclization product (m/z 741.43) was observed for dim-5-LSEPAELTDAVK 
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at 15% relative intensity (Appendix-1 Figure A1.5e), which reports the bond cleavage at the N-
terminus. 
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Figure 4.3: MS/MS spectrum of dim-4-YGGFLR. 
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 Scheme 4.5: Mechanism of f1 production from dim-3 derivatized peptides. 
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Scheme 4.6: Imido lactone formation at the N-terminus of dim-4-, dim-5-, and dim-6-YGGFLR. 
 
4.3.5 Another preferential cleavage pathway of dim-4-, dim-5-, and dim-6-Peptides 
Two ions related to cleavage of the derivatizing group from the doubly-charged dim-4-
YGGFLR precursor were observed; one dominantly at m/z 114.10 (f2) and the other strong ion at 
m/z 712.38 (oM, Figure 4.3). Dim-5-YGGFLR and dim-6-YGGFLR, cleaving at the same amide 
bond, also produced ion pairs at m/z 128.15 and 712.38 and at m/z 142.12 and 712.34, respectively. 
However, the relative ion intensities for the corresponding f2 ions, although strong, were not 
dominantly high for dim-5- and dim-6-YGGFLR (Figures 4.4 and 4.5). The favorable cleavage 
of the amide bond can be accounted for by the mechanism proposed in Scheme 4.7. The intensity 
differences among these ions are on the same order of the facility for intramolecular proton 
transfer, requiring the formation of a pseudo ring of 7, 8, or 9 atoms, with the increasing entropy 
penalty. Although dim-2- and dim-3-peptides have a more facile intramolecular proton transfer 
through a pseudo 5- or 6-membered ring (Schemes 4.4b and 4.5), the nucleophilic attack of the 
deprotonated dimethylamine to the carbon of protonated amide would experience high ring 
constraints; the generation of similar f2 ions would require the formation of a ring with three or 
four atoms following the mechanism in Scheme 4.7. Protonated aziridin-2-ones, however, are 
viable intermediates for a1 ions of peptides upon collisional dissociation (Scheme 4.4b) [29]. 
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Figure 4.5: MS/MS spectrum of dim-6-YGGFLR. 
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Scheme 4.7: N,N-Dimethyl lactam ion loss from dim-4-, dim-5-, and dim-6-YGGFLR. 
 
4.3.6 ER-MS to categorize peptides into active and passive derivatization groups 
ER-MS is an excellent tool to evaluate the energy requirements for the generation of 
fragment ions and elucidation of fragmentation patterns and mechanisms [28]. ER-MS was 
performed for YGGFLR and dim-2- through dim-6-YGGFLR. The CE profiles, in the laboratory 
frame, for the breakdown of the derivatized peptides were recorded on a triple quadrupole 
instrument.  After normalization to the initial precursor ion intensity, triplicate measurements were 
combined as a single data set for sigmoidal dose-response fitting to produce the survival curve 
(Figure 4.6), giving a CE value at 50% (CE50) of residual precursor ions. Fitting plots for all of 
the six YGGLFR peptides are shown in Appendix-1 Figure A1.8 and the formulae and the 
goodness of fitting are reported in Appendix-1 Table A1.4. CE50 values for these peptides were 
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plotted against m/z values of doubly-charged precursor ions (Figure 4.7).  Dim-2-, dim-3-, dim-4-
, and dim-5-YGGFLR correlated linearly with a slope of 0.153 and adjusted R2 of 0.9994. Together 
with the fact that different pathways operate to preferentially produce f1 and/or f2 ions and their 
complementary fragment ions (Schemes 4.4-4.7), this linear correlation suggests that these 
different mechanisms result in minimal differential effects on CE required for the breakage of 
doubly-charged precursor ions.  
The underivatized YGGFLR showed positive deviation of 1.81 volts from the linear 
correlation (Figure 4.7).  This deviation signifies the peptide as a mechanistic indicator, reporting 
that there is no special bond in the peptide which is particularly labile to gas-phase collision. The 
same is true for the positive deviation of 2.59 volts for dim-6-YGGFLR (Figure 4.7). Although 
dim-4- to dim-6-YGGFLR share a common fragmentation pathway releasing the derivatizing 
groups as N,N-dimethyl lactams (Scheme 4.7), the increased distance between the dimethylamino 
group and the amide bond formed upon the peptide derivatization leads to a discrete increase in 
the stability of intact precursors from dim-5- to dim-6-YGGFLR, shown as the positive deviation 
(Figure 4.7).  This agrees with the observation that the ε-dimethylamino group on the lysine side 
chain is a passive mass tag (Appendix-1 Figure A1.2e), stable to collisional fragmentation in the 
gas phase [10,11]. 
 120 
 
10 20 30 40 50
0
20
40
60
80
100
 Replicate 1
 Replicate 2
 Replicate 3
 Sigmoidal Fitting
R
e
la
ti
v
e
 I
n
te
n
s
it
y
 (
%
)
CE (V)
CE
50
 
Figure 4.6: Survival curve of dim-6-YGGFLR.  The precursor was selected in Q1 and Q3 with 
the CE being ramped from 5 to 35 volts in 0.5 V/s increments.  Three replicates were obtained for 
each YGGFLR peptide, and the data was normalized to the maximum intensity.  After sigmoidal 
dose-response fitting the CE50 was obtained.  
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Figure 7: CE50 and m/z Correlation for Dimethylamino YGGFLR Peptides 
 
4.3.7 Two routes for selective activation of dimethylamino peptides  
There are two general mechanisms for a derivatizing group actively participating in 
preferential fragmentations around the N-termini of derivatized peptides. Both start from the 
preferential protonation of the dimethylamino group. This proton then either: (1) transfers to the 
adjacent amide group acting as an acid catalyst to facilitate fragmentation reactions (the mobile-
proton regime) as in Schemes 4.4b, 4.5, and 4.7, or (2) directly polarizes the α-methylene carbon 
of the protonated dimethylamino group for the nucleophilic substitution by the adjacent amide 
oxygen (the charge-directed regime) as in Scheme 4.6. Proton migration from basic amino acids, 
including histidine, lysine, and arginine, has been shown to promote preferential neighboring 
cleavages [34-36].  The first general mechanism also operates in the preferential fragmentation of 
peptides derivatized with isothiocyanates [37,38].  The importance of the intramolecular proton 
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transfer is evident in this study.  When the intramolecular proton transfer becomes less favorable 
for dim-6-YGGFLR, the preferential activation of the adjacent amide bond diminishes and so do 
the subsequent fragmentation products. In comparison, proton transfer from non-methylated ε-
amine at the peptide N-terminus faces competing paths due to the complex intramolecular 
solvation of the protonated amine group [39]; therefore activation of the first amide group via acid 
catalysis confronts similar competitions.   
For the second general mechanism, although activation of the α-methylene carbon of the 
protonated dimethylamino group stays the same more or less, the direct nucleophilic substitution 
by the amide oxygen becomes less entropically favorable with the distancing of the protonated 
dimethylamino group from the neighboring amide. Succinctly, a quantized change happens from 
dim-5-YGGFLR to dim-6-YGGFLR or from active derivatization to passive derivatization 
(Scheme 4.1).  
4.4 Conclusion 
Reagents for quantitative MS are essential tools in proteomic technologies. Full utilization 
of contemporary MS advancement requires a clear appreciation of chemical principles governing 
the gas-phase fragmentation of derivatized peptides [40]. In certain applications, active cleavage 
of the derivatizing group is preferred to produce quantitative reporter ions and simple spectra of 
sequence ions for concurrent peptide identification; common examples are proteomic peptides 
derivatized with tandem mass tagging reagents. In other applications like MRM MS, it is 
advantageous to have the derivatizing group associated with multiple fragment ions. This requires 
a derivatizing group staying passive as a ubiquitous mass tag during fragmentation processes of 
derivatized peptides [3]. Understanding the underlying principles of gas-phase chemistry of 
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derivatized peptides, as revealed by the investigational reagents in this study, can guide rational 
design of novel reagents for quantitative MS.  
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5.1 Novel mass spectrometric technologies for targeted membrane proteomics   
Mass spectrometry-based proteomics was used to absolutely and precisely quantify CFTR, 
an important transmembrane protein for cystic fibrosis.  Transmembrane proteins represent a very 
difficult analyte to accurately and precisely quantify due to their high molecular weight and 
hydrophobic domains.  A surrogate, peptide-level measurement of CFTR was exploited, to avoid 
these quantitative problems.  This was further enhanced by dual protein-level enrichment 
strategies: cell-surface biotinylation and GEE [1]. To increase sample throughput of CFTR, 
passive mass tags, which possess a signal-enhancing dimethylamino group, were synthesized, and 
their gas-phase fragmentation evaluated [2]. The collisional fragmentation of peptides whose 
amine groups were derivatized with five linear ω-dimethylamino acids, from 2-(dimethylamino)-
acetic acid to 6-(dimethylamino)-hexanoic acid were investigated.  A separation of five methylene 
groups, between the terminal dimethylamino group and the amide formed upon peptide 
derivatization, is required to shut down the active participation of the terminal dimethylamino 
group. These tags are potential, new reagents for uMRM MS.  This throughput technology adapts 
a modular design that separates quantitation and sample throughput.  This allows one common IS 
to be used as the quantitation standard.  By using non-isotopic derivatizing reagents, inexpensive 
and unprecedented sample throughput is possible.  This technique is adaptable from a few samples 
to potentially hundreds. 
5.2 The need to rapidly develop tests in a clinical setting   
With the ever-increasing catalog of biomarkers for disease and treatment, the desire to 
rapidly develop clinical assays is of upmost importance to scientist, clinicians, and patients [3,4]. 
Mass spectrometry provides a flexible platform to rapidly perform this quantitative analysis [5]. 
There is no need for the lengthy and expensive production of immunograde, monoclonal 
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antibodies.  Also the multiplexing capabilities of mass spectrometers allows multiple analytes to 
be monitored in a single experiment.  MRM MS has been shown to be reproducible in quantifying 
proteins across laboratories [6]. These attributes make MS in the clinical setting an attractive 
alternative to immunoassays.  However, difficult or low abundance analytes, such as CFTR, 
represent quantitative challenges, which must be overcome by the development new tools, 
technologies, and methods. 
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Text A1.1 
2-aminoacetic acid (8 mmol) was dissolved in 5 mL of 88% formic acid (125 mmol) and 
1 mL of 37% formaldehyde (36 mmol).  The solution was refluxed at 100°C for 1h.  After heating, 
1 mL of concentrated HCl was added. The solvent was dried in vacuo, after which a white 
precipitate was obtained.  The precipitate was washed with 5 mL of glacial acetic acid 3 times.  
The product was recrystallized in methanol and diethyl ether. The yield was 29.6%.  1H NMR (400 
MHz, D2O, 25C): δ = 4.06 (s, 2H), 3.01 (s, 6H) ppm; HRMS (DART) calculated [M+H]+ 
104.0712, found 104.0671. 
Text A1.2 
3-aminopropanoic acid (8 mmol) was dissolved in 5 mL of 88% formic acid (125 mmol) 
and 1 mL of 37% formaldehyde (36 mmol).  The solution was heated via microwave irradiation at 
110°C, 100 W for 1h.  After microwave heating 1 mL of concentrated HCl was added. The solvent 
was dried in vacuo, after which a white precipitate was obtained.  The precipitate was washed with 
5 mL of glacial acetic acid 3 times.  The product was recrystallized in methanol and diethyl ether. 
The yield was 86.7%.  1H NMR (400 MHz, D2O, 25C): δ = 3.47 (t, J = 6.7 Hz, 2H), 2.96 (s, 6H), 
2.93 (t, J = 6.7 Hz, 2H) ppm; HRMS (DART) calculated [M+H]+ 118.0868, found 118.0871. 
Text A1.3 
4-aminobutanoic acid (8 mmol) was dissolved in 5 mL of 88% formic acid (125 mmol) 
and 1 mL of 37% formaldehyde (36 mmol).  The solution was heated via microwave irradiation at 
110°C, 100 W for 1h. After microwave heating 1 mL of concentrated HCl was added.  The solvent 
was dried in vacuo, after which a white precipitate was obtained.  The precipitate was washed with 
5 mL of glacial acetic acid 3 times.  The product was recrystallized in methanol and diethyl ether. 
The yield was 84.1%.  1H NMR (400 MHz, D2O, 25C): δ = 3.22 (t, J = 8.2 Hz, 2H), 2.94 (s, 6H), 
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2.54 (t, J = 7.2 Hz, 2H), 2.12-2.01 (m, 2H) ppm; HRMS (DART) calculated [M+H]+ 132.1025, 
found 132.1047. 
Text A1.4 
5-aminopentanoic acid (8 mmol) was dissolved in 5 mL of 88% formic acid (125 mmol) 
and 1 mL of 37% formaldehyde (36 mmol).  The solution was heated via microwave irradiation at 
110°C, 100 W for 1h. After microwave heating 1 mL of concentrated HCl was added.  The solvent 
was dried in vacuo, after which a white precipitate was obtained.  The precipitate was washed with 
5 mL of glacial acetic acid 3 times.  The product was recrystallized in methanol and diethyl ether. 
The yield was 29.2%.  1H NMR (400 MHz, D2O, 25C): δ = 3.19 (t, J = 8.1 Hz, 2H), 2.91 (s, 6H), 
2.49 (t, J = 7.1 Hz, 2H), 1.84-1.68 (m, 4H) ppm; HRMS (DART) calculated [M+H]+ 146.1181, 
found 146.1166. 
Text A1.5 
6-aminohexanoic acid (8 mmol) was dissolved in 5 mL of 88% formic acid (125 mmol) 
and 1 mL of 37% formaldehyde (36 mmol).  The solution was heated via microwave irradiation at 
110°C, 100 W for 2h. After microwave heating 1 mL of concentrated HCl was added.  The solvent 
was dried in vacuo, after which a white precipitate was obtained.  The precipitate was washed with 
5 mL glacial of acetic acid 3 times.  The product was recrystallized in methanol and diethyl ether. 
The yield was 20.8%.  1H NMR (400 MHz, D2O, 25C): δ = 3.17 (t, J = 8.1 Hz, 2H), 2.90 (s, 6H), 
2.44 (t, J = 7.3 Hz, 2H), 1.82-1.63 (m, 4H), 1.48-1.38 (m, 2H) ppm; HRMS (DART) calculated 
[M+H]+ 160.1338, found 160.1386. 
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Figure A1.1a: Non-derivatized NSILTETLHR [M+2H]2+ MS/MS spectrum (y ions that are 
doubly charged are denoted as y2+). 
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Figure A1.1b: Non-derivatized NSILTETLHR [M+3H]3+ MS/MS spectrum (y ions that are 
doubly charged are denoted as y2+). 
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Figure A1.1c: Non-derivatized LSLVPDSEQGEAILPR [M+2H]2+ MS/MS spectrum (y ions that 
are doubly charged are denoted as y2+). 
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Figure A1.1d: Non-derivatized LSEPAELTDAVK [M+2H]2+ MS/MS spectrum (y ions that are 
doubly charged are denoted as y2+). 
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Figure A1.1e: Non-derivatized SVILLGR [M+2H]2+ MS/MS spectrum (y ions that are doubly 
charged are denoted as y2+). 
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Figure A1.1f: Non-derivatized YGGFLR [M+2H]2+ MS/MS spectrum. 
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Figure A1.2a: Dim-2 derivatized NSILTETLHR [M+2H]2+ MS/MS spectrum. 
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300
0
10
20
30
40
50
60
70
80
90
100
[
o
M- H
2
O]
+
[*b
4
- H
2
O]
+
[*b
2
- H
2
O]
+
 
*a
3
*a
2
*b
3
*b
2
y
7
y
6
y
1
382.19
372.19
m/z
58.07
175.12
200.10
287.14
269.12
259.13
400.21
526.29
756.32
869.46
y
4
*b
1
f
1
DIM-2-NSILTETLHR
[M+2H]
2+
 634.85
R
e
la
ti
v
e
 I
n
te
n
s
it
y
 (
%
)
1165.58
 
 
 
 
 
 
 
 
 
 
 
 145 
 
Figure A1.2b: Dim-2 derivatized NSILTETLHR [M+3H]3+ MS/MS spectrum. 
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Figure A1.2c: Dim-2 derivatized LSLVPDSEQGEAILPR [M+2H]2+ MS/MS spectrum. 
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Figure A1.2d: Dim-2 derivatized LSLVPDSEQGEAILPR [M+3H]3+ MS/MS spectrum. 
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Figure A1.2e: Dim-2 derivatized LSEPAELTDAVK [M+2H]2+ MS/MS spectrum (y ions 
carrying the derivatizing group, on the lysine’s side chain amine, are denoted as *y). 
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Figure A1.2f: Dim-2 derivatized SVILLGR [M+2H]2+ MS/MS spectrum. 
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Figure A1.3a: Dim-3 derivatized NSILTETLHR [M+2H]2+ MS/MS spectrum. 
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Figure A1.3b: Dim-3 derivatized NSILTETLHR [M+3H]3+ MS/MS spectrum. 
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Figure A1.3c: Dim-3 derivatized LSLVPDSEQGEAILPR [M+2H]2+ MS/MS spectrum. 
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Figure A1.3d: Dim-3 derivatized LSLVPDSEQGEAILPR [M+3H]3+ MS/MS spectrum. 
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Figure A1.3e: Dim-3 derivatized LSEPAELTDAVK [M+2H]2+ MS/MS spectrum (y ions 
carrying the derivatizing group, on the lysine’s side chain amine, are denoted as *y). 
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Figure A1.3f: Dim-3 derivatized SVILLGR [M+2H]2+ MS/MS spectrum. 
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Figure A1.4a: Dim-4 derivatized NSILTETLHR [M+3H]3+ MS/MS spectrum. 
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Figure A1.4b: Dim-4 derivatized LSLVPDSEQGEAILPR [M+2H]2+ MS/MS spectrum. 
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Figure A1.4c: Dim-4 derivatized LSLVPDSEQGEAILPR [M+3H]3+ MS/MS spectrum. 
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Figure A1.4d: Dim-4 derivatized LSEPAELTDAVK [M+2H]2+ MS/MS spectrum. 
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Figure A1.4e: Dim-4 derivatized SVILLGR [M+2H]2+ MS/MS spectrum (y ions carrying an 
imido lactone on the lysine’s side chain amine are denoted cy). 
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Figure A1.5a: Dim-5 derivatized NSILTETLHR [M+2H]2+ MS/MS spectrum. 
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Figure A1.5b: Dim-5 derivatized NSILTETLHR [M+3H]3+ MS/MS spectrum. 
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Figure A1.5c: Dim-5 derivatized LSLVPDSEQGEAILPR [M+2H]2+ MS/MS spectrum. 
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Figure A1.5d: Dim-5 derivatized LSLVPDSEQGEAILPR [M+3H]3+ MS/MS spectrum. 
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Figure A1.5e: Dim-5 derivatized LSEPAELTDAVK [M+2H]2+ MS/MS spectrum (y ions 
carrying the derivatizing group, on the lysine’s side chain amine, are denoted as *y). 
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Figure A1.5f: Dim-5 derivatized SVILLGR [M+2H]2+ MS/MS spectrum. 
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Figure A1.6a: Dim-6 derivatized NSILTETLHR [M+2H]2+ MS/MS spectrum. 
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Figure A1.6b: Dim-6 derivatized NSILTETLHR [M+3H]3+ MS/MS spectrum. 
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Figure A1.6c: Dim-6 derivatized LSLVPDSEQGEAILPR [M+2H]2+ MS/MS spectrum. 
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Figure A1.6d: Dim-6 derivatized LSLVPDSEQGEAILPR [M+3H]3+ MS/MS spectrum. 
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Figure A1.6e: Dim-6 derivatized LSEPAELTDAVK [M+2H]2+ MS/MS spectrum (y ions 
carrying the derivatizing group, on the lysine’s side chain amine, are denoted as *y). 
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Figure A1.6f: Dim-6 derivatized SVILLGR [M+2H]2+ MS/MS spectrum. 
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Figure A1.7a: Charge state shift of SVILLGR (top) and dim-2-SVILLGR (bottom). 
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Figure A1.7b: Charge state shift of YGGFLR (top) and dim-2-YGGFLR (bottom). 
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Figure A1.7c: Charge state shift of LSLVPDSEQGEAILPR (top) and dim-2- 
LSLVPDSEQGEAILPR (bottom). 
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Figure A1.8: Sigmoidal dose-response fitted precursor survival curves of YGGFLR peptides 
(normalized). 
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Equation A1.1: Percent of chemical conversion 
After the reaction between the 5-peptide mix and the derivatizing dimethylated amino acid was 
quenched, an equal amount of isotopic SVIL[L-13C6
15N]GR was added.  After desalting, LC-MS 
was performed.  The following equation was then applied based on intensity to calculate the PCC. 
𝑃𝐶𝐶 =
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝐼𝑠𝑜𝑡𝑜𝑝𝑖𝑐 𝑆𝑉𝐼𝐿𝐿𝐺𝑅 −  𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑆𝑉𝐼𝐿𝐿𝐺𝑅
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝐼𝑠𝑜𝑡𝑜𝑝𝑖𝑐 𝑆𝑉𝐼𝐿𝐿𝐺𝑅
× 100% 
 
Equation A1.2: Signal yield for mass spectrometry 
After the reaction between the 5-peptide mix and the derivatizing dimethylated amino acid was 
quenched, an equal amount of isotopic SVIL[L-13C6
15N]GR was added.  After desalting, LC-MS 
was performed.  The following equation was then applied based on intensity to calculate the 
SYMS. 
𝑆𝑌𝑀𝑆 =
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝐷𝑒𝑟𝑖𝑣𝑎𝑡𝑖𝑧𝑒𝑑 𝑆𝑉𝐼𝐿𝐿𝐺𝑅
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝐼𝑠𝑜𝑡𝑜𝑝𝑖𝑐 𝑆𝑉𝐼𝐿𝐿𝐺𝑅
× 100% 
 
Equation A1.3: Adjusted signal yield for mass spectrometry 
To account for an inefficient reaction, the following equation was developed to predict SYMS if 
the reaction went to 100% completion. 
𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑆𝑌𝑀𝑆 =
𝑆𝑌𝑀𝑆
𝑃𝐶𝐶
 × 100% 
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Table A1.1: Collisional energy optimization for non-derivatized peptides. 
Non-Derivatized Peptide Multiplication Factor for CE 
NSILTETLHR [M+2H]2+ 1.15 
NSILTETLHR [M+3H]3+ 1.1 
LSLVPDSEQGEAILPR [M+2H]2+ 1.1 
LSEPAELTDAVK [M+2H]2+ 1.1 
SVILLGR [M+2H]2+ 1.1 
YGGFLR [M+2H]2+ 1.25 
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Table A1.2: Collisional energy optimization for derivatized peptides. 
Dimethylamino Derivatized Peptide Multiplication Factor for CE 
NSILTETLHR [M+2H]2+ 1.25 
NSILTETLHR [M+3H]3+ 1.25 
LSLVPDSEQGEAILPR [M+2H]2+ 1.1 
LSLVPDSEQGEAILPR [M+3H]3+ 1.1 
LSEPAELTDAVK [M+2H]2+ 1.15 
SVILLGR [M+2H]2+ 1.4 
YGGFLR [M+2H]2+ 1.5 
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Table A1.3: Properties of the peptide mix. 
Peptide Mass (Da) Number of Amino 
Acids 
Isoelectric Point 
NSILTETLHR 1183.32 10 7.55 
LSLVPDSEQGEAILPR 1723.93 16 3.93 
YGGFLR 711.81 6 9.34 
SVILLGR 756.94 7 10.55 
LSEPAELTDAVK 1272.41 12 3.93 
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Table A1.4: Formulae and goodness of fit for the sigmoidal dose-response fitting of the survival 
curve for the dimethylamino peptides. 
𝒚 = 𝑨𝟏 +
𝑨𝟐 − 𝑨𝟏
𝟏 + 𝟏𝟎𝒍𝒐𝒈(𝒙𝟎−𝒙)×𝒑
 
Peptide A1 A2 Logx0 p Reduced 
χ2 
Adjusted 
R2 
Non-
Derivatized 
0.002328 0.999005 15.699651 -0.244595 0.001484 0.9916 
Dim-2 0.021004 1.00113 20.392597 -0.190917 0.006084 0.9654 
Dim-3 -0.014948 1.00080 21.466005 -0.176504 0.005218 0.9704 
Dim-4 0.002769 0.995858 22.800792 -0.166370 0.008025 0.9574 
Dim-5 -0.016008 0.996510 23.644762 -0.130546 0.01062 0.9408 
Dim-6 -0.002919 0.999499 27.274779 -0.189113 0.001272 0.9916 
 
 
